

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY

WASHINGTON, D.C. 20460

OFFICE OF PREVENTION, PESTICIDES AND TOXIC SUBSTANCES

MEMORANDUM:

DATE:

August 31, 2000

SUBJECT: Office of Pesticide Programs List of Chemicals Evaluated for Carcinogenic Potential

FROM:

William L. Burnam, Chief

Science Analysis Branch

Health Effects Division (7509C)

TO:

Division Director HED, RD, SRRD and EFED

Associate Directors, HED Branch Chiefs, HED

The attached list provides a quick overview of compounds evaluated for carcinogenicity by the Health Effects Division (HED) of the Office of Pesticide Programs (OPP). Chemicals evaluated by other review groups are listed as well and HED looks to these evaluations until an internal HED evaluation has been performed. Since the evaluation of many of these chemicals is an ongoing process, the information on this list may change and become out of date, i.e., the classification and Q_1^* may change. Therefore, the list should not be used as the sole reference, without checking on the present status of a compound. Updated lists will be distributed in the future on a semi-annual basis.

Unless otherwise indicated, the classification of chemicals is based on the HED carcinogenicity peer review process or the HED hazard identification assessment review process, applying the Agency guidelines for carcinogenicity assessment. Evaluations by other groups are indicated by their acronyms: Cancer Assessment Group (CAG), Carcinogen Risk Assessment Verification Endeavor (CRAVE) and Office of Research and Development, U.S. EPA (ORD). For those chemicals where different groups suggested different classifications, the "final" OPP classification is listed under the column "Current OPP Classification and Date of Classification." The Potency (Q_I^*) , unless otherwise indicated, is based on the oral route. The units for the oral and inhalation Q_I^* are $(mg/kg/day)^{-1}$ and $(\mu g/cu.m)^{-1}$, respectively.

If any corrections are necessary or further information is required please contact Rick Whiting (Phone: 703-305-5473; Email: whiting.rick@epa.gov) or myself (Phone: 703-305-6193; Email: burnam.william@epa.gov).

1986 EPA WEIGHT-OF-THE EVIDENCE CATEGORIES			
(Feder	al Register / Vol. 51, No. 185 / September, 24 1986)		
Group A – Human Carcinogen	This group is used only when there is sufficient evidence from epidemiologic		
	studies to support a casual association between exposure to the agents and		
	cancer.		
Group B – Probable Human	This group includes agents for which the weight of the evidence of human		
Carcinogen	carcinogenicity based on epidemiologic studies is "limited" and also includes		
	agents for which the weight of the evidence of carcinogenicity based on		
	animal studies is "sufficient." The group is divided into tow subgroups.		
	Usually, Group B1 is reserved for agents for which there is limited evidence		
	from epidemiologic studies. It is reasonable, for practical purposes, to		
	regard an agent for which there is "sufficient" evidence of carcinogenicity in		
	animals as if it presented a carcinogenic risk to humans. Therefore, agents		
	for which there is "sufficient" evidence from animal studies and for which		
	there is "inadequate evidence" or "no data" from epidemiologic studies		
Group C. Dossible Human	would usually be categorized under Group B2.		
Group C – Possible Human	This group is used for agents with limited evidence of carcinogenicity in		
Carcinogen	animals in the absence of human data. It includes a wide variety of		
	evidence, e.g., (a) a malignant tumor response in a single well-conducted		
	experiment that does not meet conditions for sufficient evidence, (b) tumor		
	responses of marginal statistical significance in studies having inadequate design or reporting, (c) benign but not malignant tumors with an agent		
	showing no response in a variety of short-term tests for mutagenicity, and (d)		
	responses of marginal statistical significance in a tissue known to have a		
	high or variable background rate.		
Group D – Not classifiable as	This group is used for agents with inadequate human and animal evidence of		
to Human Carcinogenicity	carcinogenicity or for which no data are available.		
Group E – Evidence of Non-	This group is used for agents that show no evidence for carcinogenicity in at		
Carcinogenicity for Humans	least two animal tests in different species or in both adequate epidemiologic		
	and animal studies.		
	The designation of an agent as being in Group E is based on the available		
	evidence and should not be interpreted as a definitive conclusion that the		
	agent will not be a carcinogen under any circumstances.		
+1FB1			

1996 PROPOSED EPA WEIGHT-OF-THE EVIDENCE CATEGORIES			
	(http://www.epa.gov/ORD/WebPubs/carcinogen/)		
Known/Likely	This category of descriptors is appropriate when the available tumor effects and other key data are adequate to convincingly demonstrate carcinogenic potential for humans; it includes:		
	 Agents known to be carcinogenic in humans based on either epidemiologic evidence of a combination of epidemiologic and experimental evidence, demonstrating causality between human exposure and cancer, Agents that should be treated as if they were known human carcinogens, based on a combination of epidemiologic data showing a plausible causal association (not demonstrating it definitively) and strong experimental evidence. Agents that are likely to produce cancer in humans due to the production or anticipated production of tumors by modes of action that are relevant or assumed to be relevant to human carcinogenicity. 		
	Modifying descriptors for particularly high or low ranking in the "known/likely" group can be applied based on scientific judgement and experience and are as follows:		
	 agents that are likely to produce cancer in humans based on data that are at the high end of the weights of evidence typical of this group, agents that are likely to produce cancer in humans based on data that are at the low end of the weights of evidence typical of this group. 		
Cannot be determined	This category of descriptors is appropriate when available tumor effects or other key data are suggestive or conflicting or limited in quantity and, thus, are not adequate to convincingly demonstrate carcinogenic potential for humans. In general, further agent specific and generic research and testing are needed to be able to describe human carcinogenic potential. The descriptor cannot be determined is used with a subdescriptor that captures the rationale:		
	 agents whose carcinogenic potential cannot be determined, but for which there is suggestive evidence that raises concern for carcinogenic effects, agents whose carcinogenic potential cannot be determined because the existing evidence is composed of conflicting data (e.g., some evidence is suggestive of carcinogenic effects, but other equally pertinent evidence does not confirm any concern), agents whose carcinogenic potential cannot be determined because there are inadequate data to perform an assessment, agents whose carcinogenic potential cannot be determined because no data are available to perform an assessment. 		
Not likely	This is the appropriate descriptor when experimental evidence is satisfactory for deciding that there is no basis for human hazard concern, as follows (in the absence of human data suggesting a potential for cancer effects):		
	 agents not likely to be carcinogenic to humans because they have been evaluated in at least two well conducted studies in two appropriate animal species without demonstrating carcinogenic effects, agents not likely to be carcinogenic to humans because they have been appropriately evaluated in animals and show only carcinogenic effects that have 		

- been shown not to be relevant to humans (e.g., showing only effects in the male rat kidney due to accumulation of alpha_{2u}-globulin),
- agents not likely to be carcinogenic to humans when carcinogenicity is dose or route dependent. For instance, not likely below a certain dose range (categorized as likely by another route of exposure). To qualify, agents will have been appropriately evaluated in animal studies and the only effects show a dose range or route limitation or a route limitation is otherwise shown by empirical data,
- agents not likely to be carcinogenic to humans based on extensive human experience that demonstrates lack of effect (e.g., phenobarbital).

1999 DRAFT EPA WEIGHT-OF-THE EVIDENCE CATEGORIES			
	ww.epa.gov/ncea/raf/car2sab/preamble.pdf)		
Carcinogenic to humans	This descriptor is appropriate when there is convincing epidemiologic		
	evidence demonstrating causality between human exposure and cancer.		
	This descriptor is also appropriate when there is an absence of		
	conclusive epidemiologic evidence to clearly establish a cause and		
	effect relationship between human exposure and cancer, but there is		
	compelling evidence of carcinogenicity in animals and mechanistic information in animals and humans demonstrating similar mode(s) of		
	carcinogenic action. It is used when all of the following conditions are		
	met:		
	There is evidence in a human population(s) of association of		
	exposure to the agent with cancer, but not enough to show a causal		
	association, and		
	There is extensive evidence of carcinogenicity, and		
	The mode(s) of carcinogenic action and associated key events have		
	been identified in animals, and		
	The key events that precede the cancer response in animals have		
	been observed in the human population(s) that also shows evidence		
	of an association of exposure to the agent with cancer		
Likely to be carcinogenic to humans	This descriptor is appropriate when the available tumor effects other key		
	data are adequate to demonstrate carcinogenic potential to humans.		
	Adequate data are within a spectrum. At one end is evidence for an		
	association between human exposure to the agent and cancer and strong		
	experimental evidence of carcinogenicity in animals; at the other, with		
	no human data, the weight of experimental evidence shows animal carcinogenicity by a mode or modes of action that are relevant or		
	assumed to be relevant to humans.		
Suggestive evidence of	This descriptor is appropriate when the evidence from human or animal		
carcinogenicity, but not sufficient to	data is suggestive of carcinogenicity, which raises a concern for		
assess human carcinogenic potential	carcinogenic effects but is judged not sufficient for a conclusion as to		
	human carcinogenic potential. Examples of such evidence may include;		
	a marginal increase in tumors that may be exposure-related, or evidence		
	is observed only in a single study, or the only evidence is limited to		
	certain high background tumors in one sex of one species. Dose-		
	response assessment is not indicated for these agents. Further studies		
Data are in-1	would be needed to determine human carcinogenic potential.		
Data are inadequate for an	This descriptor is used when available data are judged inadequate to		
assessment of human carcinogenic potential	perform an assessment. This includes a case when there is a lack of pertinent or useful data or when existing evidence is conflicting, e.g.,		
	some evidence is suggestive of carcinogenic effects, but other equally		
	pertinent evidence does not confirm a concern.		
Not likely to be carcinogenic to			
humans			
	may be based on:		
	Extensive human experience that demonstrates lack of carcinogenic		
	effect (e.g., phenobarbital)		
Not likely to be carcinogenic to humans	This descriptor is used when the available data are considered robust for deciding that there is no basis for human hazard concern. The judgement may be based on: • Extensive human experience that demonstrates lack of carcinogenic		

- Animal evidence that demonstrates lack of carcinogenic effect in at least two well-designed and well conducted studies in two appropriate animal species (in the absence of human data suggesting a potential for cancer effects).
- Extensive experimental evidence showing that the only carcinogenic effects observed in animals are not considered relevant to humans (e.g., showing only effects in the male rat kidney due to accumulation of α2u-globulin).
- Evidence that carcinogenic effects are not likely by a particular route of exposure.
- Evidence that carcinogenic effects are not anticipated below a defined dose range.

	ACRONYMS
2/3, 3/4	This scaling factor converts the unit risk from animals to humans. The 3/4's (2/3) scaling factor could be defined as mg chemical per kg animal body weight raised to the 3/4's per day cross-species scaling factor. It would be written as: mg chemical/kg animal body weight ^ 3/4 day. The 3/4's scaling factor is now used instead of the 2/3.
CAG	Cancer Assessment Group
CARC	Cancer Assessment Review Committee (replaced HCPRC)
CRAVE	Carcinogen Risk Assessment Verification Endeavor
Date of Classification	The stamp date of the final OPP document. For CAG, CRAVE or IRIS the data represents when the document was listed on IRIS.
Def. or Defer	Deferred
F	Female(s)
HCPRC	Health Effects Division Carcinogenicity Peer Review Committee
HAZID or HIARC	Hazard Identification Assessment Review Committee (replaced RFDC)
HED	Health Effects Division
(I)	Inhalation $Q_1^* (\mu g/cu.m)^{-1}$
Int.	Interim
IRIS	Integrated Risk Information System (http://www.epa.gov/iris/)
M	Male(s)
MOE	Margin of Exposure
(O)	Oral Q ₁ * (mg/kg/day) ⁻¹
OHEA	Office of Health and Environmental Assessment, Office of Research and Development
OPP	Office of Pesticide Programs
ORD	Office of Research and Development
Q1*, Q* or (q)	Cancer Potency Q ₁ * value [Oral - (mg/kg/day) ⁻¹ and Inhalation (μg/cu.m) ⁻¹]
RFDC	Health Effects Division Reference Dose/Peer Review Committee
SAB	Scientific Advisory Board
SAP	FIFRA Scientific Advisory Panel

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS	
2,4-D CAS No. 94-75-7 EPA Chem Code: 030001	D (1/29/97)	Brain astrocytomas; F344/CrL-Br rats (M)			
the low and mid-dos	es in both the male rat brain and m	t the Registrant should be required to provide additional histopatholog male mouse spleen. A better characterization of the impurities in the t o explain the conflicting results (ie, astrocytomas in male rats).	y data to include all a est materials used in b	nimals in both the	
2-Benzyl-4-chlorophenol CAS No. 120-32-1 EPA Chem Code: 062201	C (9/5/95)	Renal tubule combined adenomas/carcinomas; B6C3F1 mice (M). Renal transitional cell carcinomas; F344/N rats (F)			
Comments: [Syn. OBCP, o-Benzy	l-p-chlorophenol]				
AC 263222 (Cadre herbicide) CAS No. 81334-60-3 EPA Chem Code: 129041	E (9/27/95)				
Comments: Studies were conduc	ted using the free acid form of AC	263222. The PC Code & CASRN for the ammonium salt are 128943 & 104098	-49-9, respectively.		
AC 299,263 CAS No. 11431-32-9 EPA Chem Code: 129171	Not Likely (2/27/97)				
Acephate CAS No. 30560-19-1 EPA Chem Code: 103301	C (5/8/85)	Hepatocellular carcinomas; CD-1 mice (F)		С	
Comments: CRAVE Q* = 8.7 E-3	(0).				
Acetaldehyde CAS No. 75-07-0 EPA Chem Code: 202300	B2 (CRAVE) (1/13/88)	Nasal tumors; SPF Wistar rats (M & F). Laryngeal tumors; Syrian Golden hamsters (M & F).	2.2 E-6 (I)	B2	
Comments: This assessment is	located on IRIS. OPP has not review	wed this chemical.		,	
Acetamide CAS No. 60-35-5 EPA Chem Code:	C (5/29/90)	Liver tumors; Wistar rats (M); F344 rats (M & F).			
Comments: HCPRC considered who deficiencies in the	Comments: HCPRC considered whether or not to quantify the risk for Acetamide, and concluded that the data were not suitable for quantitative risk assessment because of deficiencies in the individual studies. Acetamide (not itself a pesticide) is a metabolite of pesticides Methomy & Thiodicarb.				
Acetochior CAS No. 34256-82-1 EPA Chem Code: 121601	B2 (1/27/92)	Nasal epithelium adenomas, thyroid cell adenoma, benign chondra of femur, basal cell tumor of stomach; CD rats (M & F). Pulmonary adenomas (M & F); liver tumors (M); CD-1 mice.	1.69 E-2 (2/3)	Pending	

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Acetone CAS No. 67-64-1 EPA Chem Code: 044101	D (CRAVE) (12/6/89)			D
Comments: Assessment based on	lack of data concerning carcinoge	nicity in humans or animals. This assessment is located on IRIS. OPP h	as not reviewed this ch	emical.
Acetophenone CAS No. 98-86-2 EPA Chem Code: 129033	D (CRAVE) (11/7/90)			D
Comments: Assessment based on	lack of data concerning carcinoge	nicity in humans or animals. This assessment is located on IRIS. OPP h	as not reviewed this ch	emical.
Acibenzolar-S-methyl CAS No. 135158-54-2 EPA Chem Code: 061402	Not likely to be carcinogenic to humans (12/9/99)	·		
	ased on the lack of evidence of ca s performed on the current technic	rcinogenicity in mice and rats and on the lack of unequivocal genotoxic al grade product.	ity in an acceptable ba	ttery of
Acifluorfen, sodium CAS No. 62476-59-9 EPA Chem Code: 114402	B2 (3/17/88)	Liver; B6C3F1 & CD-1 mice (M & F). Stomach papillomas; B6C3F mice (M & F).	1.07 E-1 (2/3)	Pending
Comments: [Syn. Tackle & Blaz	er]			
Acrinathrin CAS No. 101007-06-1 EPA Chem Code: 129141	D (7/15/96)			
Comments: RFDC concluded that	dose selection in the 2-year rat	study was inadequate.		
Acrolein CAS No. 107-02-8 EPA Chem Code: 000701	C (CRAVE) (12/2/87)	Adrenal cortical adenomas; Fischer 344 rats (F).		C
Comments: Classification is a	lso based on carcinogenic potenita	l of metabolite, Glycidaldehyde. This assessment is located on IRIS. O	PP has not reviewed thi	s chemical.
Acrylamide CAS No. 79-06-1 EPA Chem Code: 600008	B2 (CRAVE) (5/25/88)	Benign &/or malignant tumors at multiple sites in M & F rats (F344), & carcinogenic effects in a series of 1-year limited bioassays in mice (SENCAR, Swiss-ICR & A/J strains) by several routes of exposures.	4.5 E+0 (0) 1.3 E-3 (I)	В2
Comments: This assessment is	located on IRIS. OPP has not revie	wed this chemical.		
Acrylonitrile CAS No. 107-13-1 EPA Chem Code: 000601	B1 (CRAVE) (2/11/87)	Significant increase in incidence of lung cancer in exposed workers & observation of tumors, generally astrocytomas in the brain, in 2 rat strains exposed by various routes (water, gavage, inhalation).	5.4 E-1 (0) 6.8 E-5 (I)	B1
Comments: This assessment is	located on IRIS. OPP has not revie	wed this chemical.		

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Alachlor CAS No. 15972-60-8 EPA Chem Code: 090501	Likely (high doses); Not likely (low doses) (6/27/97)	Increased incidences of malignant & combined benign/malignant multi- ple tumor types in both sexes; Long Evans rat		
		sed for the purpose of risk assessment. The consensus of the HCPRC was ted for a risk management decision.	that MOEs for both the	malignant
Aldicarb (Temik) CAS No. 116-06-3 EPA Chem Code: 098301	E (OPP)(9/15/98) D (CRAVE) (8/26/87)			D
Comments: CRAVE assessment is	located on IRIS.			
Aldrin CAS No. 309-00-2 EPA Chem Code: 045101	B2 (CRAVE) (3/22/87)	Liver carcinomas; C3HeB/Fe mice (M & F); Hepatic hyperplasia & begnign hepatomas; C3H mice (M & F); Hepatocellular carcinomas; B6C3F1 mice (M).	1.7 E+1 (0) 4.9 E-3 (I)	B2
Comments: This assessment is	located on IRIS. OPP has not revie	wed this chemical.		
Aminopyridine, 4- CAS No. 504-24-5 EPA Chem Code: 069203	D (CRAVE) (5/30/89)			D
Comments: Assessment based or	n lack of data concerning carcinoge	nicity in humans or animals. This assessment is located on IRIS. OPP h	as not reviewed this ch	nemical.
Amitraz (Baam) CAS No. 33089-61-1 EPA Chem Code: 106201	C(q) (10/31/90)	Lymphoreticular tumors; CFLP mice (F). Hepatocellular adenomas, carcinomas & adenomas/carcinomas combined; B6C3F1 mice (F); Lung adenomas; B6C3F1 mice (M).	4.97 E-2 (2/3)	
Amitrole CAS No. 61-82-5 EPA Chem Code: 004401	B2 (11/30/92)	Thyroid (malignant & benign tumors); Charworth Farms, Fischer 344 & Wistar rats (M & F). Liver (malignant & bengin tumors); B6C3F1 & NMRI mice (M & F).	1.13 E+0	
Aniline CAS No. 62-53-3 EPA Chem Code: 251400	B2 (CRAVE) (6/3/87)	Induction of tumors of the spleen and the body cavity in 2 strains of rat (CD-F & Fischer 344).	5.7 E-3	B2
Comments: This assessment is	located on IRIS. OPP has not revie	wed this chemical.		
Aramite CAS No. 140-57-8 EPA Chem Code: 062501	B2 (CRAVE) (1/10/91)	Liver tumors &/or neoplastic nodules in three strains of M & F rats (FDRL, CFN & Osborne-Mendel) & M of one strain of mice (C57BL/6XC3H/Anf)F1. Extrahepatic biliary system tumors in dogs (mongrel).	2.5 E-2 (0) 7.1 E-6 (I)	B2
Comments: This assessment is	located on IRIS. OPP has not revie	wed this chemical.		

OFFICE OF PESTICIDE PROGRAMS LIST OF CHEMICALS EVALUATED FOR CARCINOGENIC POTENTIAL

PAGE: 4

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Assert (with 128841) CAS No. 69969-22-8 EPA Chem Code: 128843	D (6/11/87)	Positive trend for hemangiomas/hemangiosarcomas in CD-1 mice (M).		Deferred
Comments: Although Assert was repeated.	classified as a Category D oncoge	n, the rodent carcinogenicity studies were of good quality and it was r	ecommended that they no	t be
Asulam CAS No. 3337-71-1 <u>EPA Chem Code: 106901</u>	C (2/17/88)	Malignant thyroid C-cell tumors; Benign adrenal pheochromocytomas; Sprague-Dawley rats (M).		
Atrazine CAS No. 1912-24-9 EPA Chem Code: 080803	C(q) (4/27/89)	Mammary tumors; Sprague-Dawley rats (F).	1.12 E-1 (3/4)	Pending
Comments: New carcinogenicity	classification pending.			
Avermectin B1 CAS No. 65195-55-3 EPA Chem Code: 122804	E (6/27/96)			
Azafenidin CAS No. 68049-83-2 EPA Chem Code: 119016	Data are inadequate for an assessment of human carcinogenic potential (10/18/99)			
related. Thus under to be carcinogenic no additional cance	the Agency's Draft Cancer Risk As: to humans." After some discussion r studies were needed nor would the	mors to be treatment-related whereas an equal number of the CARC did no sessment Guidelines (July, 1999), the second group thought that the ove, the CARC agreed that the consensus classification should be into the ere be any quantification of human cancer risk. However, the CARC recorded effects on the hematopoietic system.	rall classification was "Data are inadequate" c	"Not likely ategory but
Azinphos-methyl (Guthion) CAS No. 86-50-0 EPA Chem Code: 058001	Not likely (4/20/98)			
Comments: Repeat of rat carci	nogenicity study is requested.			
Azobenzene CAS No. 103-33-3 EPA Chem Code: 007401	B2 (CRAVE) (2/3/88)	Invasive sarcomas in the spleen & other abdominal organs; F344 rats (M & F).	1.1 E-1 (0) 3.1 E-5 (I)	B2
	oxic & may be converted to benziding	ne, a known human carcinogen, under the acidic conditions in the stomach	n. This assessment is lo	ocated on
Azoxystrobin CAS No. 131860-33-8 EPA Chem Code: 128810	Not Likely (1/14/97)			

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Bardac 22 (also 2250, 2280) CAS No. 7173-51-5 EPA Chem Code: 069149	E (8/30/94)			
Baygon (Propoxur) CAS No. 114-26-1 EPA Chem Code: 047802	B2 (6/17/96)	Bladder carcinomas (rare), papillomas & combined combined carcinoma/ papilloma (M&F); Wistar rats. Statistically significant increases in hepatocellar adenomas & adenomas & combined adenoma/carcinoma; B6C3F1 mice (M).	3.69 E-3 (3/4)	Pending
Comments: HCPRC recommended t	the low dose extrapolation (Q1*) me	odel applied to the animal data be used for the quantification of human	risk.	
Bendiocarb CAS No. 22781-23-3 EPA Chem Code: 105201	Not likely (12/16/97)			
Benomyl CAS No. 17804-35-2 EPA Chem Code: 099101	C(q) (4/7/89)	Liver tumors (hepatocellular adenomas & carcinomas) in 2 genetically related strains of mice (CD-1 & Swiss SPF) (M & F)	2.39 E-3 (3/4)	
	drolyses to MBC in an aqueous envio	ronment. MBC also appears to be the initial metabolite in mammalian syst	ems. MBC has similar o	rincreas
Benoxacor CAS No. 98730-04-2 EPA Chem Code: 911508	Cannot be determined, but suggestive (7/22/97)	Increases in glandular stomach (forestomach) tumors in both sexes of mice and rats; CD-1 & Sprague-Dawley rats		
Comments: HCPRC recommended t	hat for risk assessment purposes,	an MOE approach should be used based on the most sensitive precursor st	omach lesion.	
Bensulide CAS No. 741-58-2 EPA Chem Code: 009801	Not likely (6/10/99)			
Bentazon (Basagran) CAS No. 25057-89-0 EPA Chem Code: 275200	E (11/10/93)			
Benzene CAS No. 71-43-2 EPA Chem Code: 008801	Known human carcinogen (1/19/00) (IRIS)	Acute nonlymphocytic leukemia (ANLL), suggestive evidence for chronic nonlyphocytic leukemia (CNLL) & chroni lymphocytic leukemia (CLL) Other neoplastic conditions associated with an incr risk in humas are hematologic neoplasms, blood disorders (preleukemia & aplastic anemia), Hodgkin's lymphoma & myelodysplastic syndrome (MDS).	1.5 E-2 to 5.5 E-2 2.2 E-6 to 7.8 E-6	Known

Comments: This assessment is located on IRIS. OPP has not reviewed this chemical. Human data are supported by animals studies. The experimental animal data add to the argument that exposure to benzene increases the risk of cancer in multiple species at multiple organ sites (hematopoietic, oral & nasal, liver, forestomach, preputial gland, lung, ovary & mammary gland). The oral slope factor as reported in IRIS is 1.5 x 10E-2 to 5.5 x 10E-2 per (mg/kg/day). The inhalation risk estimate is reported as a range, from 2.2 x 10E-6 to 7.8 x x 10E-6 per ug/cu.m.

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Benzoic acid CAS No. 65-85-0 EPA Chem Code: 009101	D (CRAVE) (3/1/89)			D
Comments: Assessment based on chemical.	lack of data concerning carcinoge	enicity in humans & inadequate animal data. This assessment is located or	n IRIS. OPP has not rev	viewed this
Bifenthrin (Talstar) CAS No. 82657-04-3 EPA Chem Code: 128825	C (4/29/92)	Hemangiopericytomas in the urinary bladder; Hepatocellular carcinomas & combinded hepatocellular adenomas & carcinomas; Swiss Webster mice (M)		Deferred
Comments: HCPRC recommended t	hat for the purpose of risk charac	terization, the Reference Dose (RfD) approach should be used for quanti	fication of human risk.	
Biphenyl, 1,1- CAS No. 92-52-4 EPA Chem Code: 017002	D (CRAVE) (12/6/90)			D
Comments: Assessment based on chemical.	the lack data concerning carcinog	enicity in humans & inadequate animal data. This assessment is located o	on IRIS. OPP has not re	viewed this
Bis(chloroethyl)ether (BCEE) CAS No. 111-14-4 EPA Chem Code: 029501	B2 (CRAVE) (7/23/86)	Increased evidence of hepatomas; (C57B1/6 x C3H/Anf)F1 mice (M & F) and (C57B1/6 x AKR)F1 mice (M).	1.1 E+0 (0) 3.3 E-4 (1)	B2
Comments: This assessment is	located on IRIS. OPP has not revie	wed this chemical. [Syn. Dichloroethyl]		
Borax CAS No. 1303-96-4 EPA Chem Code: 011102	E (11/24/93)			
Boric acid CAS No. 10043-35-3 EPA Chem Code: 011001	E (11/24/93)			
Boron CAS No. 7440-42-8 EPA Chem Code: 128945	E (11/24/93)			
Bromacil CAS No. 314-40-9 EPA Chem Code: 012301	C (1/13/93)	Liver tumors (carcinomas & combined adenomas/carcinomas); CD-1 mice (M). Thyroic tumors (C-cell adenomas & follicular cell combined adenomas/carcinomas); Crl:CD (BR) rats (M).		
Comments: HCPRC recommended t	hat for the purpose of risk charac	terization, the Reference Dose (RfD) appraoch should be used for quantit	<u>fication of human risk.</u>	
Bromotrichloromethane CAS No. 75-62-7 EPA Chem Code: 008708	D (CRAVE) (1/10/91)			D
Comments: Assessment based on chemical.	lack of data concerning carcinoge	enicity in humans or animals. This assessment is located on IRIS. OPP ha	as not reviewed this	

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Bromoxynil CAS No. 1689-84-5 EPA Chem Code: 035301	C(q) (3/12/97)	Statistically significant increases in hepatocellular adenomas and/ or carcinomas and combined adenomas/carcinomas; CD-1 mice (M & F).	1.03 E-1 (3/4)	
Bromuconazole CAS No. 116255-48-2 EPA Chem Code: 120503	E (4/24/95)			
Bronopol CAS No. 52-51-7 EPA Chem Code: 216400	E (6/16/95)			
Buprofezin CAS No. 69327-76-0 EPA Chem Code: 275100	Suggestive evidence of carcino- genicity, but not sufficient to assess human carcinogenic potential (3/15/00)	Significant increase by pair-wise comparison w/the controls for combined hepatocellular adenomas/carcinomas in females; CD-1 mice		
Comments: The Committee reco	ommended that no quantification is r	equired because the evidence was limited to one sex of one species.		
Butachlor (Machete) CAS No. 23184-66-9 EPA Chem Code: 112301	Likely (2/26/99)	Multiple tumors in multiple sites in Sprague-Dawley rats including rare stomach tumors in F, rare kidney tumors in M & F, as well as tumors of the nasal mucosa and thyroid glands in M & F.		
Comments: For the linear low levels tested. Fo	w-dose (Q1*) approach, extrapolation or the non-linear, margin of exposur	of risk should be based on the occurrence of renal cortical cell tumor e (MOE) approach, extrapolation of risk should be based on the stomach,	s in both sexes of ra nasal and thyroid tur	ts at all dose
Butylate (Sutan) CAS No. 2008-41-5 EPA Chem Code: 041405	E (11/25/92)			
Cacodylic acid CAS No. 75-60-5 EPA Chem Code: 012501	B2 (7/27/94)	Urinary bladder tumor; Fischer 344 rats (M & F). Fibrosarcomas (multiple organs); B6C3F1 mice (F).	6.23 E-2 (3/4)	ס (1991)
Cadmium CAS No. 7440-43-9 EPA Chem Code:	B1 (CRAVE)(11/12/86)	Limited evidence from occupational epidemiologic studies. Evidence of carcinogenicity in rats mice by inhalation and intramuscular & subcutaneous injection.	1.8 E-3 (I)	B1
Comments: This assessment is	located on IRIS. OPP has not revie	wed this chemical.		
Cadusafos (Ebufos/Rugby) CAS No. 95465-99-9 EPA Chem Code: 128864	E (5/28/92)			
Captafol CAS No. 2939-80-2 EPA Chem Code: 081701	B2 (5/19/89)	Lymphosarcomas & hemangiosarcomas (M & F), harderian gland adenomas (M) CD-1 mice. Mammary fibroadenoma (M & F), renal adenomas/carcinomas (combined) (M); Sprague-Dawley rats (M).	5.1 E-2 (2/3)	

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Captan CAS No. 133-06-2 EPA Chem Code: 081301	82 (7/20/88)	Renal cortical/tubular cell neoplasms; CD rats (M); Uterine sarcomas Wistar rats (F). Intestinal tumors (M & F); B6C3F1, ICR CD-1 & CR CD-1 mice.	2.4 E-3 (3/4)	Pending
Carbaryl CAS No. 63-25-2 EPA Chem Code: 056801	C(q) (10/5/98)	Hemangiosarcomas (malignant vascular tumors) & combined hemagiomas/ hemangiosarcomas; CRL:CD-1 (ICR)BR mice (M).	1.19 E-2 (3/4)	
was much discussion cancer risk; HCPRC	regarding the method of quantitat	in mice & rats but at dose levels considered to be excessively toxic fo ion with the use of a low dose extrapolation (Q1*) approach and a MOE a sented. In addition, an RfD approach would be provided to assess the mo	pproach for quantificat	ion of human
Carbofuran CAS No. 1463-66-2 EPA Chem Code: 090601	Not likely (6/17/97)			
Carbon tetrachloride CAS No. 56-23-5 EPA Chem Code: 016501	B2 (CRAVE) (12/4/86)	Hepatocellur carcinomas; Osborne-Mendel, Japanese & Wistar rats; B6C3F1, C3H, A, Y, C and L mice; Syrian golden hamsters.	1.3 E-1 (0) 1.5 E-5 (I)	B2
Comments: This assessment is	located on IRIS. OPP has not review	wed this chemical.		
Carfentrazone-ethyl CAS No. 128639-02-1 EPA Chem Code: 128712	Not likely (3/24/98)			
Chloramben CAS No. 133-90-4 EPA Chem Code: 029901	Deferred			
Comments: HCPRC requested rev required. Rereview	iewer to re-tabulate data for both 1979 rat study & 1978 mouse study.	NCI studies; including data for pooled controls & results of the data	audit; historical contro	ols are also
Chlordane CAS No. 57-74-9 EPA Chem Code: 058201	B2 (CRAVE) (4/1/87)	Benign & malignant liver tumors; C57B1/6N, CD-1, B6C3F1 & ICR mice (M & F); F344 rats (M).	1.3 E+0 (O) 3.7 E-4 (I)	В2
Comments: Chlordane is structu	urally related to other known live	r carcinogens. This assessment is located on IRIS. OPP has not reviewed	this chemical.	
Chlordimeform CAS No. 6164-98-3 EPA Chem Code: 059701	B2 (12/20/85)	Malignant hemangioendothelomas; Tif:MAG:SPF mice (M & F).	1.3 E+O (Diet) 9.4 E-1 (Occupation)	

Comments: Tumor was observed in 3 studies - Chlordimeform & its two metabolites [N-formyl-4 chloro-o-toluidine & 5-CAT].

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Chlorfenapyr (Pirate) CAS No. 122453-70-0 EPA Chem Code: 129093	Cannot be determined, but suggestive (1/9/97)	The overall evidence in animals was not persuasive, but could not be dismissed. Increased in tumors in rats occurred with significant positive trends only, and mainly at the highest dose.		
Chloroaniline, p- CAS No. 106-47-8 EPA Chem Code: 017203	B2 (4/27/95)	Spleen (fibrosarcomas, hemangiosarcomas & osteosarcomas) (M); Adrenal (pheochromocytomas) (M & F); F344/N rats. Hepatocellular adenomas/carcinomas (M); Hemangiosarcomas in spleen and/or liver (M) B6C3F1	6.38 E-2 (3/4)	
Comments: p-Chloroaniline is a	a metabolite of Dimilin.			
Chlorobenzene CAS No. 108-90-7 EPA Chem Code: 056504	D (CRAVE) (4/4/90)			D
Comments: Assessment is based not reviewed this cl		animal data & predominantly negative genetic toxicity data. This asse	ssment is located on IF	RIS. OPP has
Chloroform CAS No. 97-66-3 EPA Chem Code: 020701	B2 (CRAVE) (8/26/87)	Kidney tumors; Osborne-Mendel rats (M). Hepatocellular carcinomas; B6C3F1 mice (M & F); Hepatomas; A and NLC strain mice (F).	6.1 E-3 (0) 2.3 E-5 (1)	B2
Comments: This assessment is	located on IRIS. OPP has not revie	wed this chemical.		
Chlorothalonil CAS No. 1897-45-6 EPA Chem Code: 081901	Likely (10/27/97)	Renal adenomas & carcinomas, both sexes of rats & mice; rarity of the tumor response in the kidney; papillomas and/or carcinomas of the forestomach in rats & mice; CD-1 mice; Fischer 344 & Osborne- Mendel rats.	7.66 E-3 (3/4)	Pending
Comments: HCPRC recommended th	nat a non-linear appraoch to risk	assessment, using MOE, should be used.		
Chlorpropham (CIPC) CAS No. 101-21-3 EPA Chem Code: 018301	E (10/11/94)	·		
Chlorpyrifos CAS No. 2921-88-2 EPA Chem Code: 059101	E (11/23/93)			
Cinch (Cinmethylin) CAS No. 87818-31-3 EPA Chem Code: 128837	D (4/7/89)			

Comments: HCPRC concluded there was no substantial biological evidence of tumor formation in mice or rats, however, dosing in both studies were inadequate for determining carcinogenic potential. Additional studies are requested.

OFFICE OF PESTICIDE PROGRAMS LIST OF CHEMICALS EVALUATED FOR CARCINOGENIC POTENTIAL

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Clodinafop-propargyl CAS No. 105511-96-4 EPA Chem Code: 125203	Likely to be carcinogenic to humans (12/7/99)	Prostate gland adenomas & combined adenomas/carcinomas (M); Ovarian tubular adenomas (F); Tif:RAIf(SPF) rats. Hepatomas and combined hepatomas/carcinomas (M&F); Hemangiomas & angiosarcomas (F); Tif:MAGf(SPF) mice.	1.29 E-1 (3/4)	
Comments: For the quantificat type. This approach	ion of human cancer risk, the Comm is supported by possible genotoxi	ittee recommended a linear low-dose extrapolation (Q1*) approach based c potential & the lack of confirmation of the mode of action of Clodina	on the most potent of t	he tumors
Clofentezine (Apollo) CAS No. 74115-24-5 EPA Chem Code: 125501	C (4/3/90)	Increased incidence of benign & malignant thyroid follicular cell adenoma/carcinoma; Sprague-Dawley rat	3.76 E-2 (3/4)	C
dose or Maximum Tole	erated Dose (MTD) predicted by sub- erm study using higher doses may b	than the upper limit of the historical control range & was increased a chronic studies. HCPRC also concluded that no quantification of risk wo e necessary to support appropriate characterization & quantification of	uld be done at the pres	ent time &
Cloransulam-methyl (XDE-565) CAS No. 147150-35-4 EPA Chem Code: 129116	Not likely (9/30/97)			
Copper (metallic) CAS No. 7440-50-8 EPA Chem Code: 022501	D (CRAVE) (9/15/87)			D
Comments: Assessment based on chemical.	lack of human data & inadequate as	nimal data from assays of copper compounds. This assessment is located	on IRIS. OPP has not re	viewed this
Coumaphos CAS No. 56-72-4 EPA Chem Code: 036501	E (11/22/94)			
Creosote CAS No. 8001-58-9 EPA Chem Code: 025004	B1 (CRAVE) (5/13/87)	Limited evidence of the association between occupational creosote contact & subsequent tumor formation, sufficient evidence of local & distant tumor formation after dermal application to mice.		B1 .
Comments: This assessment is	located on IRIS. OPP has not review	wed this chemical.		
Cresol, p-Chloro-m- CAS No. 59-50-7 EPA Chem Code: 064206	D (11/28/95)			
Comments: HCPRC concluded the	evidence is inadequate & cannot be	e interpreted as showing either the presence or absence of a carcinogen	ic effect.	
Cryolite (Kryocide) CAS No. 15096-52-3 EPA Chem Code: 075101	D (1/26/93)			
Comments: Assessment based on	inadequate animal data.			

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Cyanazine (Bladex) CAS No. 21725-46-2 EPA Chem Code: 100101	C(q) (7/30/91)	Mammary gland tumors (adenocarcinoma, carcinosarcoma); Sprague- Dawely rat (F).	1.0 E-0	Pending
Cyclanilide CAS No. 113136-77-9 EPA Chem Code: 026201	Not likely (4/9/97)			
Cyhalothrin/Karate CAS No. 68085-85-8 EPA Chem Code: 128867	D (9/15/94)			
Comments: Due to the equivocation should be classified		use study & in view of the inadequacy of the dose levels tested, the R	FDC concluded that the o	chemical
Cyhexatin (TCTH) CAS No. 13121-70-5 EPA Chem Code: 101601	Not likely to be carcinogenic to humans (8/1/00)			
Cymoxanil CAS No. 57966-95-7 EPA Chem Code: 129106	Not likely (1/21/98)			
Cypermethrin CAS No. 52315-07-8 EPA Chem Code: 109702	C (9/27/88)	Benign lung adenomas (increase in both adenomas and adenomas/ carcinomas combined); Alderly Park SPF Swiss strain mice (F).		
Cyproconazole (SAN 619F) CAS No. 94361-06-5 EPA Chem Code: 128993	B2 (12/04/92)	Hepatocellular adenomas & carcinomas; CD-1 mice (M & F).	3.02 E-1 (2/3)	
	sed on the possible clastogenic aci lack of adequate rat carcinogenici	tivity of Cyproconazole, tumors in mice & rats administered structural ty study.	ly-related analogues fro	om the same
Cyprodinil CAS No. 121552-61-2 EPA Chem Code: 288202	Not likely (1/14/98)			
Cyromazine (Larvadex) CAS No. 66215-27-8 EPA Chem Code: 121301	E (1/6/95)			
Comments: Metabolite is Mela	nine.			
DDD CAS No. 72-54-8 EPA Chem Code: 029101	B2 (CRAVE) (6/24/87)	Lung tumors (M & F), liver tumors (M); CF-1 mice. Thyroid tumors (follicular cell adenomas & carcinomas); Osborne-Mendel rats (M).	2.4 E-1	B2
Comments: This assessment is	located on IRIS. OPP has not revie	wed this chemical.		<u> </u>

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
DDE CAS No. 72-55-9 EPA Chem Code:	B2 (CRAVE) (6/24/87)	Liver tumors; B6C3F1 mice (hepatocellular carcinomas) (M & F); CF-1 mice (hepatomas) (M & F). Liver (neoplastic nodules); Syrian Golden Hamsters (M & F). Thyroid tumors; Osborne-Mendel rats (F).	3.4 E-1	B2
Comments: This assessment is	located on IRIS. OPP has not revi	ewed this chemical.		
DDT CAS No. 50-29-3 EPA Chem Code: 029201	B2 (CRAVE) (6/24/87)	Tumors (generally of the liver) were observed in 7 studies in various mouse strains [BALB/C, CF-1, A strain, Swiss/Bomaby & (C57B1)x(C3HxAkR)] and in 3 rat studies (Wistar, MRC Porton & Osborne-Mendel).	3.4 E-1 (0) 9.7 E-5 (I)	B2
Comments: This assessment is	located on IRIS. OPP has not revi	ewed this chemical.	-	
DEET CAS No. 134-62-3 EPA Chem Code: 080301	D (1/4/96)			
Comments: Dosing for male ra	its was considered inadequate. [Syn	. N,N-Diethyl-metatoluamide]	···	
Dacthal (DCPA) CAS No. 1861-32-1 EPA Chem Code: 078701	C(q) (2/10/95)	Thyroid tumors (M & F); Hepatocellular adenoma/carcinoma/hepato- choloangiocarcinoma (F); Sprague-Dawley rats. Hepatocellular adenomas & combined adenoma/carcinoma; CD-1 mice (F).	1.49 E-3 (3/4)	
Daminozide (Alar) CAS No. 1596-84-5 EPA Chem Code: 035101	B2 (7/26/91)	Multiple sites (eg. lungs, vessels, liver & kidney); Multiple species, strains & studies.	8.7 E-3	
Comments: SAP recommended re	peating carcinogenicity studies.			
Dazomet CAS No. 533-74-4 EPA Chem Code: 035602	D (12/7/93)	Equivocal evidence of hepatocellular tumors; B6C3F1 mice (F).		
	at the existing genotoxicity data	for Dazomet are predominantly positive, & concluded additional testing m	ay be necessary, if th	ère are
Desmedipham CAS No. 13684-56-5 EPA Chem Code: 104801	E (7/26/94)			
Di(2-ethylhexyl)phthalate CAS No. 117-81-7 EPA Chem Code: 295200	B2 (CRAVE) (10/7/87)	Hepatocellular carcinomas & combined incidence of carcinomas & adenoma; Fischer 344 rats (F) and B6C3F1 mice (M & F). Neoplastic nodules & hepatocellular carcinomas; Fischer 344 rats (M).	1.4 E-2	82
Comments: This assessment is	located on IRIS. OPP has not revi	ewed this chemical. [Syn. DEHP, Bis(2-ethylhexy)phthalate]		

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Diazinon CAS No. 333-41-5 EPA Chem Code: 057801	Not likely (9/21/99)			
Dibromochloropropane (DBCP) CAS No. 96-12-8 EPA Chem Code: 011301	B2 (CAG)	Liver, kidney, stomach, nasal; Osborne-Mendel & Fischer 344 rats.	1.2 E-5 (2/3)	Pending
Comments: OPP has not reviewe	d this chemical.			
Dibromoethane, 1,2- CAS No. 106-93-4 EPA Chem Code: 042002	B2 (CRAVE) (5/13/87)	Increased incidence of a variety of tumors in rats & mice by 3 routes of administration at both the site of application and at distant sites. EDB is mutagenic in various in vitro and in vivo assays.	8.5 E+1 (0) 2.2 E-4 (I)	B2
Comments: This assessment is	located on IRIS. OPP has not revie	wed this chemical. [Syn. EDB, Ethylene dibromide]	·	
Dibutyl phthalate CAS No. 84-74-2 EPA Chem Code: 028001	D (CRAVE) (8/26/87)			D
Comments: Assessment based on	lack of data concerning carcinoge	nicity in humans or animals. This assessment is located on IRIS. OPP ha	s not reviewed this ch	emical.
Dicamba CAS No. 1918-00-9 EPA Chem Code: 029801	D (7/29/96)			Pending
Comments: The RFDC concluded	that doses selected for the rat &	mouse studies were not adequate.		
Dichlobenil CAS No. 1194-65-6 EPA Chem Code: 027401	C (7/18/95)	Adenomas alone & in combined adenoma/carcinoma at the HDT only (F); Hepatocellular adenomas and carcinomas, alone and combined (M & F); Fischer 344 rats.		
Comments: HCPRC recommended t	hat for the purpose of risk charac	terization the Reference Dose (RfD) should be used for quantification o	f human risk.	
Dichlorobenzamide, 2,6- CAS No. 2008-88-4 EPA Chem Code: 027402	Not classifiable (11/28/95)			
Comments: RFDC concluded that available for review including the carcin	w. RFDC concluded that the chemica	as presented. The tumor incidences were not adequately reported. There l is not classificable for carcinogenic potential because of the inadeq	was no mouse carcinoge uacy of the existing de	enicity study ata
Dichlorobenzene, 1,2- CAS No. 95-50-1 EPA Chem Code: 059401	D (CRAVE) (12/6/89)			D

Comments: Assessment based on lack of data concerning carcinogenicity in humans & inadequate animal data. This assessment is located on IRIS. OPP has not reviwed this chemical. [Syn. Orthodichlorobenzene]

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Dichloroethane, 1,2- CAS No. 107-06-2 EPA Chem Code: 042003	B2 (CRAVE) (12/4/86)	Induction of several tumor types in Osborne-Mendel rats & B6C3F1 mice treated by gavage and lung papillomas in ICR/HA Swiss mice after topical application.	9.1 E-2 (0) 2.6 E-5 (I)	B2
Comments: This assessment is	located on IRIS. OPP has not review	wed this chemical. [Syn. EDC]	,	
Dichloroethylene, 1,1- CAS No. 75-35-4 EPA Chem Code: 600033	C (CRAVE) (1/7/87)	Kidney adenomacarcinoma; Swiss mice (M)	6.0 E-1 (0) 5.0 E-5 (I)	c
Comments: This assessment is	located on IRIS. OPP has not review	wed this chemical. [Syn. Vinylidene chloride]		
Dichloromethane CAS No. 75-09-2 EPA Chem Code: 042004	B2 (CRAVE) (04/6/89)	Hepatocellular neoplasms & alveolar/bronchiolar neoplasms; B6C3F1 mice (M & F). Benign mammary tumors (M & F), salivary gland sarcomas (M), leukemia (F); F344 rats.	7.5 E-3 (0) 4.7 E-7 (I)	B2
Comments: This assessment is	located on IRIS. OPP has not review	wed this chemical.		
Dichloropropene, 1,3- CAS No. 542-75-6 EPA Chem Code: 029001	B2 (12/8/89)	Forestomach, liver, mammary, thyroid, adrenal, urinary & lung tumors; Fischer 344 rats & B6C3F1 mice (M & F). Bronchioloaveolar adenomas; B6C3F1 mice (M).	1.22 E-1 (3/4) (0)	B2
Comments: [Syn. Telone II]				
Dichlorvos (DDVP) CAS No. 62-73-7 EPA Chem Code: 084001	Suggestive evidence of carcino- genicity, but not sufficient to assess human carcinogeic potential (3/1/00)		7.68 E-2 (3/4)	B2
limit its usefulnes: are also limited in	s for human risk assessment. 2) The their use for human risk assessme of human exposure, indicates that a	ation: 1) MCL in the M Fischer rat has certain properties in terms of vertices for the second of the	asma & RBC ChE & cholir	nergic signs, oute. which
Diclofop-methyl (Hoelon) CAS No. 51338-27-3 EPA Chem Code: 110902	Likely to be carcinogenic to humans (5/24/00)	Liver tumors were seen in both sexes of two species including both benign & malignant liver tumors in Wistar rats & B6C3F1 mice. Increases in the incidence of thyroid follicular cell tumors in F rats & Leydig cell tumors in M rats were possibly treatment-related.	7.36 E-2 (3/4)	
Comments: CARC recommended a observed in mice. The	linear low-dose (Q1*) extrapolation his approach is supported by the la	n approach for the quantification of human cancer risk based on the mos ack of confirmation of the mode of action.	st potent of the liver t	umors
Dicofol (Kelthane) CAS No. 115-32-2 EPA Chem Code: 010501	C (6/24/92)	Liver tumors (adenomas/carcinomas); B6C3F1 mice (M)		Deferred

Comments: HCPRC recommended that for the purpose of risk characterization the Reference Dose (RfD) approach should be used for quantification of human risk.

OFFICE OF PESTICIDE PROGRAMS LIST OF CHEMICALS EVALUATED FOR CARCINOGENIC POTENTIAL

PAGE: 15

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS			
Dicrotophos (Bidrin) CAS No. 141-66-2 EPA Chem Code: 035201	Suggestive evidence of carcino- genicity, but not sufficient to assess human carcinogenic potential (10/18/99)	Increasing trend for thyroid follicular cell adenomas; C57BL/10 J CD-1 Alpk mice (M & F)					
Comments: CARC recommended th human risk characte	at an in vivo comet assay on the terization no quantification for can-	arget organ be conducted to examine possible interaction with DNA. The cer risk is required.	Committee recommended t	hat for			
Dieldrin CAS No. 60-57-1 EPA Chem Code: 045001	B2 (CRAVE) (3/5/87)	Effects range from benign liver tumors to hepatocarcinomas with transplantation confirmation, to pulmonary metastases; M & F mice (C3HeB/Fe, C3H, CF1, B6C3F1, C3H/HE & C57B1/6J)	1.6 E+1 (0) 4.6 E-3 (I)	В2			
Comments: This assessment is	located on IRIS. OPP has not revi	ewed this chemical.					
Diethyl phthalate CAS No. 84-66-2 EPA Chem Code: 128947	D (CRAVE) (8/26/87)			D			
Comments: Assessment based on	lack of data concerning carcinoge	nicity in humans or animals. This assessment is located on IRIS. OPP I	has not reviewed this ch	emical.			
Difenoconazole (Dividend) CAS No. 119446-68-3 EPA Chem Code: 128847	C (7/27/94)	Statistically significant increases in liver adenomas, carcinomas & combined adenomas/carcinomas; CD-1 mice (M & F).	3.94 E-2 (3/4)				
Comments: Tumors were observe ization, the Margin	d at doses which were considered to of Exposure (MOE) approach should	be excessively high for carcinogenicity testing. HCPRC recommended the used for quantification of human risk.	nat for the purpose of r	isk charact-			
Difenzoquat methyl sulfate CAS No. 43222-48-6 EPA Chem Code: 106401	E (5/24/94)						
Diflubenzuron (Dimilin) CAS No. 35367-38-5 EPA Chem Code: 108201	E (4/27/95)		ĺ				
Comments: p-Chloroaniline is	Comments: p-Chloroaniline is a metabolite.						
Diflufenzopyr-sodium CAS No. 109293-98-3 EPA Chem Code: 005107	Not likely (10/6/98)						

Comments: The HIARC had a metabolism concern for 3,5-difluoroaniline (DFA), a rat metabolite. The HIARC concluded that if significant secondary residues [meat/milk] of this minor rat urinary metabolite [<1%] occurred, then the metabolite would have to be regulated based on carcinogenicity of dichloroaniline [DCA]. Since there are no toxicological data for DCA, as per HED policy, all chloroanilines are considered to be carcinogens and a carcinogenic risk assessment will be conducted using the Q1* for Parachloroaniline (PC). The Q1* is 6.38 x 10E-2.

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS	
Dimethenamid (SAN 582H) CAS No. 87674-68-8 EPA Chem Code: 129051	C (9/15/95)	Statistically significant increasing trend for benigh combined and/ or malignant liver tumors; Sprague-Dawley rat (M). Unresolved issues regarding nasal tumors, strong mutagenicity data & SAR.		l denso	
Comments: HCPRC recommended a Subdivision F, adde		ch is the next required test after a positive dominant lethal study (as	per Mutagenicity Guide	lines,	
Dimethipin (Harvade) CAS No. 55290-64-7 EPA Chem Code: 118901	C (1/5/90)	Lung adenomas & carcinomas; CD-1 mice (M)		С	
Comments: Repeat of rat carci pending receipt of	nogenicity study is requested. Con an adquate 2-year study in the rat	sideration of whether or not a quantification of risk is to be determine	ed for Harvade was defe	rred,	
Dimethoate CAS No. 60-51-5 EPA Chem Code: 035001	C (8/29/91)	Hemolymphoreticular tumors; B6C3F1 mice (M). Spleen (hemangioma & hemangiosarcoma) skin (hemangiosarcoma), lymph (angioma and angiosarcoma) tumors; Wistar rats (M).			
Comments: HCPRC recommended f	or the purpose of risk characteriz	ation that the Reference Dose (RfD) approach should be used for quantifi	cation of human risk.		
Dimethyl ether CAS No. EPA Chem Code:	D (1/12/94)				
Comments: Assessment based in the evidence was no	adequate animal data. In a rat stu t convincing.	dy [Crl:CD(SD)BR] there was statistcal elevation in total mammary tumors	; however the HCPRC ag	reed that	
Dimethyl phthalate CAS No. 131-11-3 EPA Chem Code: 028002	D (CRAVE) (8/26/87)			D	
Comments: Assessment based on	lack of data concerning carcinoge	nicity in humans or animals. This assessment is located on IRIS. OPP has	not reviewed this cher	mical.	
Dinocap (Karathane) CAS No. 39300-45-3 EPA Chem Code: 036001	E (6/22/94)		-		
Dinoseb CAS No. 88-85-7 EPA Chem Code: 037505	C (6/19/86)	Liver adenomas; CD-1 mice (F).		D	
Comments: Repeat of rat carcinogenicity study is requested.					
Diquat dibromide CAS No. 85-00-7 EPA Chem Code: 032201	E (5/12/94)			Pending	

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Disulfoton (Disyston) CAS No. 298-04-4 EPA Chem Code: 032501	E (4/21/97)			
Dithiopyr (MON 7200) CAS No. 97886-45-8 EPA Chem Code: 128994	E (10/13/93)			
Diuron CAS No. 330-54-1 EPA Chem Code: 035505	Known/Likely (5/8/97)	Urinary bladder carcinomas; Wistar rat (M & F). Mammary gland carcinomas; NMRI mice (F). Information from structurally related analogs provided further support.	1.91 E-2 (3/4)	
	risk characterization, a low dose adder carcinomas in the male rat.	linear extrapolation (Q1*) model to be applied to the animal data for	the quantification of hu	ıman risk,
Emamectin CAS No. 137512-74-4 EPA Chem Code: 122806	Not likely (3/19/98)			
	was based on the lack of evidence nogenic potential of the chemical.	of carcinogenicity in male & female rats or male & female mice at dos	es that were judged to b	oe adequate
Endosulfan CAS No. 115-29-7 EPA Chem Code: 079401	Not likely to be carcinogenic to humans (1/31/00)			Deferred
Endrin CAS No. 72-20-8 EPA Chem Code: 041601	D (CRAVE) (10/19/88)	An NCI bioassay was suggestive of response in Osborne-Mendel rats (M $\&$ F).		D
Comments: This assessment is	located on IRIS. OPP has not revie	wed this chemical.		
Epichlorohydrin CAS No. 106-89-8 EPA Chem Code: 097201	B2 (CRAVE) (10/29/86)	Multiple studies in rats & mice administered epichlorohydrin by various routes were positive. As Epichlorohydrin is a strong alkylating agent, tumors are produced at the site of application.	9.9 E-3 (0) 1.2 E-6 (I)	B2
Comments: This assessment is	located on IRIS. OPP has not revi	ewed this chemical.		
Esfenvalerate (Asna) CAS No. 66230-04-4 EPA Chem Code: 109303	E (7/1/96)			
Comments: Data from Fenvalera	te (CAS No. 51630-58-1) was used i	n this assessment.		
Ethalfluralin (Sonalan) CAS No. 55283-68-6 EPA Chem Code: 113101	C(q) (9/14/94)	Mammary tumors (F); Suggestion of bladder tumors (F) and kidney tumors (M & F); Fischer 344 rats	8.9 E-2 (3/4)	

Comments: HCPRC considered the dose levels in the mouse study to be inadequate; however HCPRC did not recommend repeating the study.

OFFICE OF PESTICIDE PROGRAMS LIST OF CHEMICALS EVALUATED FOR CARCINOGENIC POTENTIAL

PAGE: 18

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS	
Ethametsulfuron CAS No. 97780-06-8 EPA Chem Code: 129091	Can not be evaluated (10/22/98)				
were judged to be in Ethametsulfuron, su	nadequate to assess the carcinogen	be evaluated since the highest dose tested in mice and rats did not elic potential of Ethametsulfuron. No rationale was provided for dose se to other sulfonylureas such as Bensulfuron methyl, Halosulfuron methyl).	lection. HIARC noted th	at	
Ethephon CAS No. 16672-87-0 EPA Chem Code: 099801	D (5/5/94)				
Comments: The RFDC considered evidence from the o	that the evidence from the 2 rat s ther mouse study was equivocal.	studies and 1 of the mouse studies to be inadequate to support a positiv	ve carcinogenicity find	ing, while	
Ethion CAS No. 563-12-2 EPA Chem Code: 058401	E (6/20/94)				
Ethiozin (Ebuzin/Tycor) CAS No. 64529-56-2 EPA Chem Code: 128883	Tentative C (9/12/90)	Thyroid follicular cell tumors; F344 rats (M & F).			
Comments: Quantification defe	rred pending submission & evaluation	on of additional data.			
Ethofenprox (Etofenprox) CAS No. 80844-07-1 EPA Chem Code: 128965	C(q) (5/24/90)	Combined thyroid follicular cell adenomas/carcinomas; Sprague-Dawley rats (M & F).	5.1 E-3 (2/3)		
Ethofumesate CAS No. 26225-79-6 EPA Chem Code: 110601	D (2/24/94)				
Comments: Assessment based on	the fact that the carcinogenicity	phase of the rat study & the hamster study were both considered to be	nadequate.		
Ethoprop (Ethoprophos) CAS No. 13194-48-4 EPA Chem Code: 041101	Likely (10/7/98)	Pheochromocytoma - adrenal glands (malignant); Sprague-Dawley rat rat (M); Cell carcinomas - thyroid gland; Sprague-Dawley & Fischer 344 rat (M); Evidence of clastogenicity in vitro mutagenicity testing.	2.81 E-2 (3/4)		
Comments: A liner low-dose approach for human risk characterization & extrapolation (Q1*) should be based on malignant pheochromocytomas of the adrenal glands in male rats at all dose levels tested.					
Ethylene diamine CAS No. 107-15-3 EPA Chem Code: 004205	D (CRAVE) (7/25/91)			D	

Comments: Assessment based on lack of data concerning carcinogenicity in humans or animals. This assessment is located on IRIS. OPP has not reviewed this chemical.

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Ethylene oxide CAS No. 75-21-8 EPA Chem Code: 042301	B1 (OHEA, 1985)			
Comments: OPP has not review	ed this chemical.			
Ethylene thiourea (ETU) CAS No. 96-45-7 EPA Chem Code: 600016	B2 (3/19/90)	Thyroid adenoma, carcinoma, & combined adenoma/carcinoma; F344 & CRCD rats (M & F). Thyroid adenomas & carcinoma, putuitary & liver tumors; B6C3F1 & C57BL/6 x AKR mice (M & F).	6.01 E-2 (3/4)	Pending
Fenamiphos (Nemacur) CAS No. 22224-92-6 EPA Chem Code: 100601	E (11/23/93)			
Fenarimol CAS No. 60168-88-9 EPA Chem Code: 206600	E (10/23/86)			
Fenbuconazole (Fenethanil) CAS No. 114369-43-6 EPA Chem Code: 129011	C(q) (4/15/96)	Thyroid follicular cell adenomas &/or combined adenomas/carcinomas; Sprague-Dawley rats (M). Hepatocellular carcinomas (M); Hepatocell- ular adenomas & combinded adenomas and/or carcinomas (F); CD-1 mice.	3.59 E-3 (3/4)	
Comments: HCPRC recommended used for quantific	that for the purpose of risk chara ation of human risk.	acterization a low dose extrapolation (Q1*) model applied to the experime	ental animal tumor data	should be
Fenbutatin oxide (Vendex) CAS No. 13356-08-6 EPA Chem Code: 104601	E (10/8/92)			
Fenitrothion (Sumithion) CAS No. 122-14-5 EPA Chem Code: 105901	E (7/13/93)			
Fenoxycarb CAS No. 72490-01-8 EPA Chem Code: 125301	Likely (12/22/97)	Lung adenomas, carcinomas & combined adenoma/carcinoma; Harderian gland adenomas; CD-1 mice (M).		
Comments: HCPRC recommended	a low dose extrapolation model be	applied to the animal data for the quantification of human risk.		
Fenpropathrin (Danitol) CAS No. 39515-41-8 EPA Chem Code: 127901	E (3/31/93)			
Fenpryroximate CAS No. 134098-61-6 EPA Chem Code: 129131	Not likely (2/19/97)			

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Fenthion CAS No. 55-38-9 EPA Chem Code: 053301	E (3/11/96)			
Fenvalerate (Pydrin) CAS No. 51630-58-1 EPA Chem Code: 109301	E (7/1/96)			
Comments: All food uses for	Fenvalerate have or will be transfe	erred to Esfenvalerate (CAS No. 66230-44-4). Fenvalerate data will be use	ed in the Esfenyalerate	e assessment.
Fipronil CAS No. 120068-37-3 EPA Chem Code: 129121	C (7/18/95)	Thyroid follicular cell adenomas, carcinomas & combined adenomas/ carcinomas (M); thyroid follicular cell adenomas and combined adenomas/carcinomas (F); Charles River CD rats.		
Comments: HCPRC recommended	that the RfD methodology be used for	or estimation of human risk.		
Flucarbazone sodium CAS No. 181274-17-9 EPA Chem Code: 114009	Not likely to be carcinogenic to humans (7/19/00)			
Fludioxonil (Maxim) CAS No. 13141-86-1 EPA Chem Code: 071503	D (9/19/96)	Based on increased liver tumors in rats (F) that was statistically significant for combined adenoma/carcinoma only, lack of response in M rats or either sex of the mouse & need for additional mutagenicity studies.		
Flumetsulam (XRD-498) CAS No. 98967-40-9 EPA Chem Code: 129016	E (6/23/93)			
Flumiclorac pentyl CAS No. 87546-18-7 EPA Chem Code: 128724	E (9/7/94)			
Fluometuron CAS No. 2164-17-2 EPA Chem Code: 035503	C(q) (8/28/96)	Statistically significant increases in combinded adenomas/carcinomas of the lung (M); Malignant lymphocytic lymphomas (F); CD-1 mice.	1.80 E-2 (3/4)	
Comments: HCPR recommened for Reference Dose app		tion, both a low dose extrapolation model (Q1*) applied to animal data (l	ung tumors in male mic	e) and the
Fluridone CAS No. 59756-60-4 EPA Chem Code: 112900	E (7/1/85)			
Fluroxypyr (DOWCO 433) CAS No. 69377-81-7 EPA Chem Code: 128959	Not likely (1/28/98)			

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Flusilazole (Nustar) CAS No. 85509-19-9 EPA Chem Code: 128835	Deferred (3/23/88)			
Comments: HCPRC recommends new	v carcinogenicity studies in M & F	in both the rat and mouse.		
Fluthiacet-methyl (Action) CAS No. 117337-19-6 EPA Chem Code: 108803	Likely (12/8/98)	Pancreatic cell tumors (exocrine adenomas, islet cell adenomas, and combined islet cell tumors); Sprague-Dawley rats (M). Hepatocellular tumors (adenomas and combined adenoma/carcinoma); CD-1 mice (M & F).	2.07 E-1 (3/4)	
adenoma/carcinoma ir	n male mice. Although both tumor this tumor type was observed at a	human characterization & determined that extrapolation should be based types (pancreatic cell & hepatocellular) are of concern, the hepatocell lower dose (10 mg/kg/day) in mice compared to the pancreatic cell tumo	ular tumors were selec	ted for
Flutolanil (Moncut) CAS No. 66332-96-5 EPA Chem Code: 128975	E (6/9/94)			
Folpet CAS No. 133-07-3 EPA Chem Code: 081601	B2 (9/4/86)	Duodenum (carcinoma & adenoma); CD-1 & B6C3F1 mice (M & F); Hyperkeratosis/acanthosis; B6C3F1 mice (M).	1.86 E-3 (3/4)	B2
Comments: Additional informati	ion for the rat studies has been r	equested.		
Fomesafen (Flex) CAS No. 72128-02-0 EPA Chem Code: 123802	C(q) (8/27/86)	Liver tumors (adenomas, carcinomas, & adenomas/carcinomas combined); CD-1 mice (M & F).	1.9 E-1 (2/3)	С
Fonofos (Dyfonate) CAS No. 944-22-9 EPA Chem Code: 041701	E (11/10/93)			
Formaldehyde CAS No. 50-00-0 EPA Chem Code: 043001	B1 (CRAVE) (2/3/88)	Statistically significant associations between site-specific respiratory neoplasms & exposure to formaldehyde; Humans. Nasal squamous cell carcinomas; Sprague-Dawley & Fischer 344 rats, B6C3F1 mice.	1.3 E-5 (I)	B1
Comments: This assessment is l	ocated on IRIS. OPP has not review	wed this chemical.		
Formetanate hydrochloride CAS No. 23422-53-9 EPA Chem Code: 097301	E (5/20/96)			
Fosetyl-Al (Aliette) CAS No. 39148-24-8 EPA Chem Code: 123301	Not amenable to classification (7/29/92)			C

Comments: HCPRC concluded that Fosetyl-Al was not amenable to classification using current Agency cancer guidelines. The HCPRC concluded that pesticidal use of Fosetyl-Al is unlikely to pose a carcinogenic hazard to humans. [Note: CRAVE classification based on urinary bladder tumors (adenomas/carcinomas combined) in male CD rats.]

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Furmecyclox (Xyligen B) CAS No. 60568-05-0 EPA Chem Code: 122601	B2 (7/3/85)	Liver tumors (M & F); Urothelial tumors (M); Sprague-Dawley rats.	2.98 E-2 (2/3)	B2
Comments: CRAVE Q* = 3.0 E-2	(0).			
Glyphosate CAS No. 1071-83-6 EPA Chem Code: 417300	E (12/16/91)			D
Glyphosate trimesium CAS No. 81591-81-3 EPA Chem Code: 128501	E (7/26/94)			
Comments: [Syn. Sulfosate]				
HOE 107892 CAS No. 135590-91-9 EPA Chem Code: R47618	Not likely (11/24/98)			
Halosulfuron-methyl CAS No. 100784-20-1 EPA Chem Code: 128721	Not likely (2/26/98)			
Haloxyfop-methyl (Verdict) CAS No. 690806-40-2 EPA Chem Code: 125201	B2 (9/18/89)	Liver tumors [adenomas (M), carcinomas (F) & adenomas/carcinomas (M & F)]; B6C3F1 mice.	7.39 E+0 (2/3)	Pending
Comments: Assessment also bas dosage levels.	ed upon the acknowledgement by the	e registrant that the compound would be likely to cause tumors of the li	ver in rats if tested	at adequate
Heptachlor CAS No. 76-44-8 EPA Chem Code: 044801	B2 (CRAVE) (4/1/87)	Benign and malignant liver tumors (M & F) in mice (C3H & B6C3F1),	4.5 E+0 (0) 1.3 E-3 (I)	B2
Comments: This assessment is	located on IRIS. OPP has not revie	wed this chemical.		
Heptachlor epoxide CAS No. 1024-57-3 EPA Chem Code: 044801	B2 (CRAVE) (4/1/87)	Liver carcinomas; C3H & CD-1 mice (M & F); CFN rats (F).	9.1 E+0 (2/3) (0) 2.6 E-3 (2/3) (I)	
Comments: This assessment is	located on IRIS. OPP has not revi	ewed this chemical.		
Hexachlorobenzene (HCB) CAS No. 118-74-1 EPA Chem Code: 061001	B2 (CRAVE) (3/1/89)	Tumors in the liver, thyroid & kidney in rats (Sprague-Dawley, Agus & Wistar), mice (Swiss & ICR) and hamsters (Syrian Golden).	1.02 E+0 (3/4) (0)	B2
Comments: Hexachlorobenzene i	s a contaminate of PCNB & Dacthal.	OPP has revised (06/21/95) the oral Q* for HCB: 1.02 E+0.		

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Hexachlorocyclohexane CAS No. 608-73-1 EPA Chem Code: 008901	B2 (CRAVE) (12/17/86)	Benign hepatic nodules & hepatocellular carcinomas; Swiss mice (M). Liver nodules hepatomas; dd mice (M & F). Hepatomas; ICR-JCL mice (M & F).	1.8 E+0 (0) 5.1 E-4 (1)	B2
Comments: This assessment is	located on IRIS. OPP has not revie	wed this chemical. [Syn. t-HCH]	<u>.</u>	
Hexachlorocyclopentadiene CAS No. 77-47-4 EPA Chem Code: 027502	D (CRAVE) (10/5/89)			D
Comments: Assessment based on chemical.	inadequate data in humans & no da	ta in animals concerning carcinogenicity. This assessment is located on	IRIS. OPP has not revi	ewed this
Hexachloroethane CAS No. 67-72-1 EPA Chem Code: 045201	C (CRAVE) (7/23/86)	Hepatocellular carcinoma; B6C3F1 mice (M & F).	1.4 E-2 (O) 4.0 E-6 (I)	
Comments: This assessment is	located on IRIS. OPP has not revie	wed this chemical.		
Hexaconazole (Anvil) CAS No. 79983-71-4 EPA Chem Code: 128925	C(q) (9/26/90)	Benign Leydig cell tumors; Wistar (Alpk:APfSD) rat (M)	1.6 E-2 (3/4)	
	equately tested for carcinogenic p trapolation model (Q1*), was recom	otential in mice. Repeat of study not required at this time. Quantifica mended.	tion of potential human	cancer risk
Hexazinone CAS No. 51235-04-2 EPA Chem Code: 107201	D (7/27/94)	Statistically significant increasing trend in combined hepatocell- ular adenoma/carcinoma; CD-1 mice (F).		
	evidence that was equivocal (not by pairwise comparison with contr	entirely negative, but yet not convincing) since only statistically signols).	nificant increase was i	n F mice (by
Hexythiazox (Savey) CAS No. 78587-05-0 EPA Chem Code: 128849	C(q) (3/16/88)	Liver (hepatocellular carcinomas & carcinomas/adenomas combined); B6C3F1 mice (F).	2.22 E-2 (3/4)	Pending
Hydramethylnon (Amdro) CAS No. 67485-29-4 EPA Chem Code: 118401	c (3/28/91)	Lung adenomas & combined adenomas/carcinomas; CD-1 mice (F).		
Comments: HCPRC recommended t	hat for the purpose of risk charac	terization the Reference Dose (RfD) approach should be used for the qua	ntification of human ris	sk
Hydrogen cyanamide CAS No. 420-04-2 EPA Chem Code: 014002	C(q) (9/15/93)	Ovarian granulosa-theca tumors; CRL:CD-1 (ICR)BR mice (F) [Hydrogen cyanamide]. Positive trend in hemangiosarcomas; B6C3F1 mice (M) [Calcium cyanamide].	6.74 E-2 (2/3)	

Comments: Calcium cyanamide is rapidly & quantitatively converted to Hydrogen cyanamide in solution & at the pH of the human & rat gut. Thus, Calcium cyanamide studies were used as supporting data for Hydrogen cyanamide.

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Hydroprene (Altozar) CAS No. 41096-46-2 EPA Chem Code: 486300	D (6/8/95)			
Comments: Assessment based	on equivocal nature of the findings	in the rat study and the lack of a carcinogenicity study in a second sp	ecies.	
Hydroquinone CAS No. 123-31-9 EPA Chem Code:	Not classified		5.6 E-2	
Comments: Hydroquinone is a	plant metabolite of Asulam.			
Imazalil CAS No. 35554-44-0 EPA Chem Code: 111901	Likely to be carcinogenic to humans (12/7/99)	An increase (both trend and pair-wise) in combined liver adenomas/carcinomas in male Swiss albino mice & male Wistar rats and an increase in combined thyroid follicular adenomas/carcinomas in male Wistar rats.	6.11 E-2 (3/4)	
	ch is supported by the lack of conf	ation (Q1*) approach for the quantification of human cancer risk based o irmation of the mode of action. Imazalil is structurally related to tria		
Imazapyr (Arsenal) CAS No. 81334-34-1 EPA Chem Code: 128821	E (10/5/95)			
Imidacloprid CAS No. 105827-78-9 EPA Chem Code: 129099	E (11/10/93)			
Indoxacarb (DPX-MP062) CAS No. 173584-44-6 EPA Chem Code: 067710	Not likely to be carcinogenic to humans (7/17/00)			
Iprodione (Glycophene) CAS No. 36734-19-7 EPA Chem Code: 109801	Likely (11/19/97)	Hepatocellular tumors (M&F); Ovarian luteomas (F); CD-1 mice. Testicular interstitial cell tumors (Leydig cell); Crl:CD(SD)BR rats (M).	4.39 E-2 (3/4)	
Comments: CARC re-affirmed rats.	that the current linear low-dose ex	trapolation (Q1*) should be based on the liver tumors in both sexes of m	ice & the Leydig cell	tumor in male
Isofenphos CAS No. 25311-71-1 EPA Chem Code: 109401	Not likely (1/13/98)			
Isophorone CAS No. 78-59-1 EPA Chem Code: 047401	C (CRAVE) (8/5/92)	Preputial gland carcinomas; F344/N rats (M)	6.08 E-4 (3/4)	C
Comments: This assessment i	s located on IRIS. OPP has not rev	iewed this chemical.		

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Isoxaben (EL-107) CAS No. 82558-50-7 EPA Chem Code: 125851	C (1/4/89)	Hepatocellular adenomas; B6C3F1 mice (M & F).		Pending
Isoxaflutole CAS No. 14112-29-0 EPA Chem Code: 123000	likely (8/6/97)	Statistically significant increases in liver tumors in both sexes of mice & rats; statistically significant increases in thyroid tumors in male rats; CD-1 mice and Sprague-Dawley rats.		
	risk characterization, a non-linea ion (Q1*) to be applied for the tu	r approach-MOE to be applied to the most sensitive precursor lesion in mors of the rat liver.	M rat thyroid, and that	a linear
Kathon 886 (Kathon Biocide) CAS No. 55965-84-9 EPA Chem Code: 107106	D (5/18/95)			
Comments: Assessment based on	the lack of second carcinogenicit	y study in a another species.		
Kresoxim-methyl CAS No. 143390-89-0 EPA Chem Code: 129111	Likely to be carcinogenic to humans (8/19/99)	Liver tumors (hepatocellular adenomas, hepatocellular carcinomas & combined adenomas/carcinomas); Wistar rats (M & F).	2.90 E-3 (3/4)	
carcinomas in femal	acterization, CARC recommended the e rats. This extrapolation was sup of liver tumors in male & female	extrapolation of risk using the linear low-dose (Q1*) approach based or ported by the lack of confirmation of the mode of action for liver tumo rats.	n combined hepatocellul r induction & dose-depe	ar adenomas/ ndent
Lactofen (Cobra) CAS No. 77501-63-4 EPA Chem Code: 128888	B2 (4/8/87)	Hepatocellular carcinomas (M); Hepatocellular adenomas & carcinomas (M & F); CD-1 mice. Liver neoplastic nodules; Sprague-Dawley rats (M & F).	1.19 E-1 (3/4)	
Lindane CAS No. 58-89-9 EPA Chem Code: 009001	B2/C (CAG)	Liver and lung tumors (both benign); mice		
Comments: A Lindane metabolit	e, 2,4,6-trichlorophenol (TCP) is	classified as B2. OPP has not reviewed this chemical.		
Linuron CAS No. 330-55-2 EPA Chem Code: 035506	C (4/1/87)	Testicular tumors; CD rats (M); Hepatocellular adenomas; CD-1 mice (M & F).		С
MBC (Carbendazim) CAS No. 10605-21-7 EPA Chem Code: 128872	C(q) (4/7/89)	Liver tumors (hepatocellular adenomas & carcinomas) in 2 genetically related strains of mice (CD-1 & Swiss SPF) (M & F).	2.39 E-3 (3/4)	

Comments: Benomyl rapidly hydrolyses to MBC in an aqueous environment. MBC also appears to be the initial metabolite in mammalian systems. MBC has similar or increased toxicity, both acute & chronic, to Benomyl.

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
MGK Repellent 326 CAS No. 136-45-8 EPA Chem Code: 047201	B2 (7/21/93)	Multiple malignant & benign tumors [liver (M & F), kidney (M & F), testes (M) & uterine (F); CD rats. Multiple malignant tumors [liver (M & F) & lung/bronchiolar tumors (M)]; CD-1 mice.	2.4 E-3 (2/3) (M) 1.2 E-3 (2/3) (F)	
MGK-264 CAS No. 113-48-4 EPA Chem Code: 057001	C (6/7/95)	Statistically significant increases in hepatocellular adenomas; CD-1 mice (M & F). Statistically significant increases for thyroid follicular cell adenomas; Crl:CDBR rats (M).		
Comments: HCPRC recommended t	hat for the purposes of risk chara	cterization, the Reference Dose (RfD) approach should be used for quant	itation of human risk.	
MON 13900 (Furilazole) CAS No. 121776-33-8 EPA Chem Code: 911596	Likely to be carcinogenic to humans (9/21/99)	Multiple tumors were seen at multiple sites in two species including both benign & malignant liver tumors in M & F Sprague-Dawley rats & CD-1 mice, rare tumors such as stomach & testicular tumors in M rats & lung tumors in both sexes of mice.	2.74 E-2 (3/4)	
significant tumor t lung tumors in one mode of action. MON	ype was recommended. This extrapol or both sexes of rats or mice, the	, the extrapolation of risk using the linear low-dose (Q1*) approach for ation was supported by the increases in the incidence of liver, stomach potential for clastogenic effect, lack of adequate genotoxicity/mutager alachlor & acetochlor, which cause tumors at multiple sites (liver, stor carcinogenic to humans."	& testicular tumors as nicity data, as well as	well as
MON 21200 (Genesis) CAS No. 82697-71-0 EPA Chem Code: 128726	C (7/23/96)	Statistically significant increase in histiocytic sarcomas (F); CD-1 mice.		
Comments: HCPRC recommended f	or the purpose of risk characteriz	ation, the RfD approach should be used for quantitation of human risk.		
MON 4660 CAS No. 71526-07-3 EPA Chem Code: 600046	Likely to be carcinogenic to humans (12/9/99)	Hepatocellular adenomas, carcinomas & combined adenomas/carcinomas; (M&F) rats & mice. Stomach squamous cell papillomas & combined papillomas/carcinomas; M rats & M&F mice. Bile duct cholangiomas/carcinomas; M rats. Bronchio-alveolar adenomas, combined adenomas/carcinomas; M mice. Sprague-Dawley rats, CD-1 mice	4.88 E-2 (3/4)	
		(Q1*) approach for human risk characterization based on the most potent by the lack of data on the mode of action & inadequate data to assess		
MSMA CAS No. 2163-80-6 EPA Chem Code: 013803	Not likely to carcinogenic to humans (7/26/00)			
potential dietary e 6.23 x 10E-2 (mg/kg	xposure to Cacodylic acid followin	the HIARC report (7/26/00), the chronic RfD for MSMA is based on a Cacor g MSMA application. For the assessment of the lifetime cancer risk throu applied. This low dose extrapolation will not be performed for resident ed to be only to MSMA.	ugh dietary exposure, t	he Q1* of
Malathion CAS No. 121-75-5 EPA Chem Code: 057701	Suggestive evidence of carcinogenicity but not sufficient to assess human carcinogenic potential (4/28/00)	Occurrence of liver tumors in male & female B6C3F1 mice & in female Fischer 344 rats only at excessive doses (statistically significant & outside historical control). Presence of a few rare tumors, oral palate mucosa in F & nasal respiratory epithelium in M&F Fischer 344 rats. Malaoxon is not carcinogenic in M&F Fischer 344 rats.		

Comments: Quantitative risk assessment for carcinogenicity is not required since the Committee classified malathion as having suggestive evidence for cancer. A cancer dose-response assessment, e.g. low dose linear extrapolation model, is not indicated for pesticides in the "suggestive" category.

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Maleic hydrazide CAS No. 5716-15-4 EPA Chem Code: 051502	E (11/10/93)			
Mancozeb CAS No. 8018-01-7 EPA Chem Code: 014504	B2 (11/19/92)	Thyroid follicular cell adenomas & carcinomas, combined thyroid follicular cell adenomas and/or carcinomas; Crl:CD(BR) rats (M & F).	USE ETU Q*	
Maneb CAS No. 12427-38-2 EPA Chem Code: 014505	B2 (11/19/92)	Thyroid follicular cell adenomas & carcinomas, combined thyroid follicular cell adenomas and/or carcinomas; Crl:CD(BR) rats (M & F).	USE ETU Q*	
Melamine CAS No. 108-78-1 EPA Chem Code:	Not amenable to classification (7/29/92)	Transitional cell carcinomas of the urinary bladder; F344/N rats (M).		
it appears that hu genic response in concentrations far	mans are not likely to be exposed t rats. In particular, anticipated hu	ssification using the current Agency guidelines. Based on a mechanistic o doses of Melamine that produce the urinary tract toxicity that preced man dietary & occupational exposure to the parent compound, Cyromazine, parent urinary tract tumor precursors. HCPRC concluded that it is unliked usage of Cyromazine.	es & seems to lead to the is estimated to product	he carcino- e Melamine
Mepiquat chloride CAS No. 24307-26-4 EPA Chem Code: 109101	E (6/20/96)			
Mercaptobenzothiazole, 2- CAS No. 149-30-4 EPA Chem Code: 051701	C (11/19/92)	Adrenal gland tumors (M & F), some evidence of preputial gland tumors (M) & equivocal evidence for pituitary gland tumors (M); F344/N rats.		
Comments: KCPRC recommended	that for the purpose of risk charac	terization the Reference Dose (RfD) approach should be used for quantif	ication of human risk.	[Syn. MBT]
Mercury (Inorganic) CAS No. 7439-97-6 EPA Chem Code: 052301	D (CRAVE) (1/13/88)			D
Comments: Assessment based o	n lack of data concerning carcinoge	enicity in humans & inadequate animal data. This assessment is located or	n IRIS. OPP has not rev	iewed this
Metalaxyl CAS No. 57837-19-1 EPA Chem Code: 113501	E (12/31/85)			
Comments: Chemical will be r	e-evaluated when genotoxicity studi	es are reviewed.		
Metam sodium CAS No. 137-42-8 EPA Chem Code: 039003	B2 (5/1/95)	Malignant angiosarcomas (by both pair-wise & trend analysis); C57BL/10JfCD-1/Alpk mice (M & F). Malignant hemangiosarcomas; Hsd/Ola: Wistar rats (M).	1.98 E-1 (3/4)	

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Methamidophos (Monitor) CAS No. 10265-92-6 EPA Chem Code: 101201	E (10/6/97)			
Methidathion CAS No. 950-37-8 EPA Chem Code: 100301	C (2/19/88)	Liver tumors (benign and malignant); CD-1 mice (M).		С
Methiocarb (Mesurol) CAS No. 2032-65-7 EPA Chem Code: 100501	D (3/2/93)			
Comments: Assessment based on	the lack of a second carcinogenic	ity study in another species.		
Methomyl CAS No. 16752-77-5 EPA Chem Code: 090301	E (10/26/96)			
Methoxychlor CAS No. 72-43-5 EPA Chem Code: 034001	D (CRAVE) (10/7/87)			D
Comments: Assessment based on this chemical.	lack of data concerning carcinoge	nicity in humans & inconclusive data in animals. This assessment is loca	ated on IRIS. OPP has n	ot reviewed
Methyl bromide CAS No. 74-83-9 EPA Chem Code: 053201	D (CRAVE) (3/1/89)			D
Comments: Assessment based on chemical. [Syn. Bro		nicity in humans & inadequate animal data. This assessment is located or	n IRIS. OPP has not rev	iewed this
Methyl ethyl ketone (MEK) CAS No. 78-93-3 EPA Chem Code: 044103	D (CRAVE) (5/30/89)			D .
Comments: Assessment based on	lack of data concerning carcinoge	nicity in humans or animals. This assessment is located on IRIS. OPP has	s not reviewed this che	mical.
Methyl parathion CAS No. 298-00-0 EPA Chem Code: 053501	Not likely (12/1/97)			
Methylene bis(thiocyanate) CAS No. 6317-18-6 EPA Chem Code: 068102	D (5/20/96)	Benign adrenal pheochromocytomas in M and pituitary adenomas in F; Sprague-Dawley rats. Alveolar/bronchial adenomas & carcinomas; CD-1 mice (M & F). [All lesions were within historical control range].		

Comments: RFDC based classification on inadequacy of the data set and on what was considered to be a border line significance of the tumors observed in rats & mice.

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Methylphenol, 3- CAS No. 108-39-4 EPA Chem Code: 022102	C (CRAVE) (10/5/89)	Increased incidence of skin papillomas in mice in an initiation-promotion study.		С
Comments: This assessment is	located on IRIS. OPP has not revie	wed this chemical. [Syn. meta-Cresol]		
Metolachlor CAS No. 51218-45-2 EPA Chem Code: 108801	C (11/16/94)	Liver adenomas and combined adenomas/carcinomas; Charles River CD (SD)BR rats (F). [Same liver neoplasia in female rats was also observed in a separate repeat study].		С
Comments: HCPRC recommended	that a Margin of Exposure (MOE) met	chodology be used for the estimation of human risk.		
Metribuzin (Sencor) CAS No. 21087-64-9 EPA Chem Code: 101101	D (5/16/95)	Pituitary adenomas; SPF Wistar rats (F)		ם
	dy in Fischer CDF(F-344)/ BR rats w carcinomas in Fischer 344 rats (M &	was negative. Chemical structurally related to Ethiozin, which was assoc & F).	iated with thyroid cell	adenomas &
Molinate (Ordram) CAS No. 2212-67-1 EPA Chem Code: 041402	C(q) (6/17/92)	Statistically significant increase in combined adenomas & carcinomas in the kidney; Crl:CD(SD)BR rat (M). There was equivocal evidence that Molinate induced an increase in testicular tumors.	4.92 E-2 (3/4)	
Comments: HCPRC recommended for quantification		zation, a low dose extrapolation (Q1*) model applied to the experimental	animal tumor data shou	ld be used t
Myclobutanil (Systane/Rally) CAS No. 88671-89-0 EPA Chem Code: 128857	E (6/16/94)			
Naled (Dibrom) CAS No. 300-76-5 EPA Chem Code: 034401	E (8/31/94)			
Naptalam (Alanap-1) CAS No. 132-66-1 EPA Chem Code: 030702	D (9/7/94)			
Comments: Assessment based o	on the lack of an adequate mouse ca s, a new mouse study maybe required	rcinogenicity study. Naptalam is currently registered as a low volume/mid.	nor use chemical. If exp	posure or
Naptalam, sodīum salt CAS No. 132-67-2 EPA Chem Code: 030703	D (9/7/94)			
	on the lack of an adequate mouse ca es, a new mouse study maybe require	rcinogenicity study. Naptalam is currently registered as a low volume/mi d.	nor use chemical. If ex	posure or

OFFICE OF PESTICIDE PROGRAMS LIST OF CHEMICALS EVALUATED FOR CARCINOGENIC POTENTIAL

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Nicosulfuron (Accent) CAS No. 111991-09-4 EPA Chem Code: 129008	E (9/1/98)			
Nitrapyrin CAS No. 1929-82-4 EPA Chem Code: 069203	Likely to be carcinogenic to humans (5/5/00)	Increase (both pair-wise & trend) in liver & stomach tumors in B6C3F M & F mice, epididymal sarcomas in M mice & Harderian gland tumors in F mice. Nitrapyrin is structurally related to chlorinated pyridines which are mutagenic & carcinogenic in mice & rats.	4.25 E-2 (3/4)	
Comments: CARC recommended a This approach is su	liner low-dose (Q1*) extrapolation pported by the lack of adequate da	approach for the quantification of human cancer risk based on most poto ta on the mode of action & mutagenic concern for Nitrapyrin.	ent liver tumors in fer	male mice.
Nitrobenzene CAS No. 98-95-3 EPA Chem Code: 056501	D (CRAVE) (11/8/89)			D
Comments: Assessment based on	lack of data concerning carcinoge	nicity in humans or animals. This assessment is located on IRIS. OPP ha	s not reviewed this che	emcial.
Norflurazon CAS No. 27314-13-2 EPA Chem Code: 105801	C (11/2/90)	Statistically significant increase in comparison to controls in liver adenomas & combined liver adenomas & carcinomas, as well as the statistically significant positive trend for these hepatocellular adenomas & combined adenomas & carcinomas; CD-1 mice (M)		
conclusion was supp	hat for the purposes of risk chara orted by the presence of only beni and no positive analogues.	cterization the Reference Dose (RfD) approach should be used for the qu gn (and combined) tumors in only one sex of one species at one dose lev	antification of human el, and adequate but ne	risk. This egative
Orthophenylphenol & Na salt CAS No. 90-43-7 EPA Chem Code: 064103	B2 (8/24/94)	Multiple tumor types in multiple studies. Malignant urinary bladder & kidney tumors (M); Papillomas of the urinary bladder & uterine endometrium (F); F344/DuCrj & F344 rats.		
Oryzalin CAS No. 19044-88-3 EPA Chem Code: 104201	C(q) (3/12/86)	Multiple sites (thyroid, mammary); F344 rats (M & F).	1.3 E-1 (2/3)	C
Oxadiazon CAS No. 19666-30-9 EPA Chem Code: 109001	C(q) (8/27/87)	Liver tumors (malignant, combined malignant & benign); CD CD-1 mice (M & F).	1.4 E-1 (2/3)	Deferred
Oxadixyl (San 371F) CAS No. 7732-09-3 EPA Chem Code: 126701	C(q) (1/4/89)	Hepatocellular adenomas (by pair-wise comparison & with a dose-related trend); Han-Wistar rats (M & F).	5.3 E-2 (2/3)	Deferred
Oxamyl (Vydate) CAS No. 23135-22-0 EPA Chem Code: 103801	E (11/5/96)			

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Oxydemeton-methyl CAS No. 301-12-2 EPA Chem Code: 058702	Not likely (7/24/97)			
Oxyfluorfen (Goal) CAS No. 42874-03-3 EPA Chem Code: 111601	C(q) (9/29/89)	Liver (adenomas, carcinomas & combined adenomas and/or carcinomas); CD-1 mice (M).	7.32 E-2 (3/4)	
Oxytetracycline CAS No. 2058-46-0 EPA Chem Code: 006308	D (12/4/92)			
Oxythioquinox (Morestan) CAS No. 2439-01-2 EPA Chem Code: 054101	B2 (2/15/96)	Lung tumors; NMRI mice (M). Hepatocellular tumors (M & F) and rare kidney tumors (F); F344 rats. Data showing chemical has clastogenic acticity provided additional support.	3.42 E-2 (3/4)	
	or the purpose of risk characterized kidney tumors (combined adenoma)	zation, a low dose extrapolation (Q1*) model be applied to animal data f /carcinoma).	or the quantification o	of human
Paclobutrazol CAS No. 76738-62-0 EPA Chem Code: 125601	D (6/23/94)	Benign stromal polpys (F); Leydig cell tumors (M); Sprague-Dawley Crl:CD(SD)BR rats.		
	new carcinogenicity studies may be carcinogenicity data).	pe required if the current use pattern changes (i.e. food uses or uses w	hich are in the high ex	posure
Paradichlorobenzene CAS No. 106-46-7 EPA Chem Code: 061501	C (4/27/89)	Liver (adenomas and carcinomas); B6C3F1 mice (M & F).		
Paranitrophenol CAS No. 100-02-7 EPA Chem Code: 056301	D (5/14/96)			
Comments: Classification base	ed on inadequacy of the data base,	i.e. lack of carcinogenicity data in a second animal species.		
Paraquat dichloride CAS No. 1910-42-5 EPA Chem Code: 061601	E (7/28/88)			C
Comments: OPP to reevaluate w	hen new data on powdered diet are	submitted. SAP concerned with nasal squamous cell carcinoma seen in Fi	scher 344 rats (M).	
Parathion (Ethyl parathion) CAS No. 56-38-2 EPA Chem Code: 057501	C (9/11/91)	Adrenal cortical tumors (adenomas + carcinomas; Thyroid follicular cell adenomas & pancreatic cell carcinomas; Osborne-Mendel rat (M) Benign pancreatic tumors; Wistar rat (M)		C
Comments: The Committee concl (Q1*) for quantitat	luded that Parathion be classified tive risk assessment; instead a Re	as a Group C without quantification, which is to say without the use of ference Dose (RfD) approach will be used.	a low dose extrapolati	on model

toxic effects.

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Pebulate CAS No. 1114-71-2 EPA Chem Code: 041403	Not likely (12/7/98)			
Pendimethalin CAS No. 40487-42-1 EPA Chem Code: 108501	C (7/24/92)	Thyroid follicular cell adenomas; Sprague-Dawley rats (M & F).		
Comments: HCPRC recommended t	hat for the purpose of risk charac	cterization the Reference Dose (RfD) approach should be used for quantif	ication of human risk.	
Pentachloronitrobezene CAS No. 82-68-8 EPA Chem Code: 056502	C (12/18/92)	Thyroid follicular cell adenomas (by both pair-wise and trend analysis) in males with a positive trend in females; CD rats.		
Comments: HCPRC recommended 1	that for the purpose of risk charac	cterization the Reference Dose (RfD) approach should be used for quantif	ication of human risk.	[Syn. PCNB
Pentachlorophenol CAS No. 87-86-5 EPA Chem Code: 063001	B2 (1/3/91)	Hepatocellular adenomas & carcinomas, adrenal medulla pheochromocytomas & malignant pheochromocytomas, &/or hemangiosarcomas & hemangiomas in one or bothe sexes of B6C3F1 mice.	1.29 E-1 (2/3)	B2
Comments: CRAVE Q* = 1.2 E-1	(0).			
Permethrin CAS No. 52645-53-1 EPA Chem Code: 109701	C(q) (9/18/89)	Lung (adenomas & combined adenomas/carcinoma); Liver (adenoma); CD-1 mice (F).	1.84 E-2 (2/3)	Pending
Phenmedipham (Betanal) CAS No. 13684-63-4 EPA Chem Code: 098701	D (4/28/93)			
Comments: RFDC considered the	dose levels in both carcinogenic	ity studies (rat & mouse) to be inadequate.		
Phenol CAS No. 108-95-2 EPA Chem Code: 064001	D (CRAVE) (8/2/89)			D
Comments: Assessment based or chemical.	n lack of data concerning carcinog	enicity in humans & inadequate animal data. This assessment is located or	n IRIS. OPP has not re	viewed this
Phorate (Thimet) CAS No. 298-02-2 EPA Chem Code: 057201	E (12/30/93)			

Comments: This assessment is located on IRIS. OPP has not reviewed this chemical.

OFFICE OF PESTICIDE PROGRAMS LIST OF CHEMICALS EVALUATED FOR CARCINOGENIC POTENTIAL

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Phosmet (Imidan) CAS No. 732-11-6 EPA Chem Code: 059201	Suggestive evidence of carcinogenicity, but not sufficient to assess human carcinogenic potential (10/27/99)	Increase (both trend & pair-wise) in combined liver adenomas/carcinomas in male B6C3F1 mice but only trends for increase of liver adenomas/carcinomas & mammary adenocarcinomas in female B6C3F1 mice. There was no evidence of carcinogenicity in an acceptable study in Charles River rats.		
Comments: Because there is lower warranted.	w confidence that there is a potent	tial cancer risk to humans, the Committee recommended that quantification	on using the tumor data	is not
Phosphamidon CAS No. 13171-21-6 EPA Chem Code: 018201	C (5/31/89)	Bladder transitional cell carcinoma; Hepatocellular carcinoma; Sprague-Dawley rats (M).		
Comments: Quantification of o species. Furthermor	ncogenicity risk was not recommend e, the increase in the incidence o	ed since the evidence is limited & the oncogenic response was confined to tumors were not statistically significant by pairwise comparison.	to one sex of one strain	n of one
Phosphine CAS No. 7803-51-2 EPA Chem Code: 066500	D (CRAVE) (3/31/92)			D
Comments: Assessment based on this chemical.	lack of data concerning carcinoge	nicity in humans & inadequate data in animals. This assessment is locate	ed on IRIS. OPP has not	reviewed
Phostebupirim (Bay mat 7484) CAS No. 96182-53-5 EPA Chem Code: 129806	E (4/27/97)			
Picloram (+ salts) CAS No. 1918-02-1 EPA Chem Code: 005101	E (4/1/94)			
Piperonyl butoxide CAS No. 51-03-6 EPA Chem Code: 067501	C (6/7/95)	Increased incidence of hepatocellular tumors (M & F) (adenomas, carcinomas, combined adenomas/carcinomas in M and adenomas in F; CD-1 mice		
Comments: HCPRC recommended t	hat for the purpose of risk charac	terization, the Reference Dose (RfD) approach should be used for quanti	tation of human risk.	
Pirimiphos-methyl CAS No. 29232-93-7 EPA Chem Code: 108102	Can not be determined (1/29/98)			
Comments: HIARC concluded tha	t the carcinogenic potential of Pi	rimiphos-methyl can not be determined due to the lack of an acceptable	carcinogenicity study i	n rats.
Polychlorinated biphenyls CAS No. 1336-36-3 EPA Chem Code: 017801	B2 (CRAVE) (4/22/87)	Hepatocellular carcinomas; Fischer 344, Sprague-Dawley & Wistar rat; dd & BALB/cJ mice. Inadequate yet suggestive evidence of excess risk of liver cancer in humans by ingestion, inhalation or dermal contact.	7.7 E+0	В2

Comments: Q1* will be based on the incidence of liver tumors.

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Prallethrin (ETOC) CAS No. 23031-36-91 EPA Chem Code: 128772	Not likely (9/28/99)			
Primisulfuron-methyl CAS No. 86209-51-0 EPA Chem Code: 128973	D (5/3/90)	Hepatocellular adenomas & carcinomas; CD-1 mice (M & F). [The two dose levels were these tumors occurred were excessively toxic]		
Comments: HCPRC did not rec	ommend to repeat the mouse study. [S	yn. Beacon].		 .
Prochloraz CAS No. 67747-09-5 EPA Chem Code: 128851	C(q) (7/1/88)	Hepatocellular adenoma & carcinoma, combined adenoma/carcinoma; CD-1 (M & F).	1.5 E-1 (2/ 3)	С
Procymidone (Sumilex) CAS No. 32809-16-8 EPA Chem Code: 129044	B2 (4/5/91)	Interstitial cell adenoma (M); Pituitary adenoma (F); Osborne-Mendel rats. Liver adenomas & combined adenomas/carcinomas; B6C3F1 mice (F). Additionally, a rare variant of hepatocellular carcinoma, hepatoblastoma, had a significant increasing trend in M B6C3F1 mice.	2.35 E-2 (2/3) 1.92 E-2 (2/3)	
human risk (Q1*).	f risk characterization, a low dose A quantification of risk is recomme ouse & male rat, respectively.	extrapolation model applied to the experimental animal tumor data was rended for the testicular tumors in male rats and for the liver tumors in	recommended for quantif n female mice. The Q1*	ication of values are
Prodiamine (Rydex) CAS No. 29091-21-2 EPA Chem Code: 110201	C (7/15/91)	Thyroid follicular cell neoplasia; Pancreatic adenomas; Sprague- Dawley rats (M & F). Fibrosarcomas; CD-1 mice (M).		
recommendation to	use the RfD approach was based upor	ration that the Reference Dose (RfD) approach should be used for quantif n several factors including the absence of genotoxicity, the nature of t astic response at sites other than the thyroid.	ication of human risk. he response (benign th	The yroid
Profenofos (Curacron) CAS No. 41198-08-7 EPA Chem Code: 111401	E (2/6/95)	·		
Prometon CAS No. 1610-18-0 EPA Chem Code: 080804	D (9/17/92)	Mammary tumor; Sprague-Dawley rats (F)		
Prometryn CAS No. 7287-19-6 EPA Chem Code: 080805	E (7/25/94)			
Pronamide (Kerb) CAS No. 23950-58-5 EPA Chem Code: 101701	B2 (5/26/93)	Benign testicular interstitial cell tumors (M); Uncommon thyroid follicular cell adenomas (M&F); Crl:CD(SD)BR rats. Hepatocellular carcinomas; B6C3F1 mice (M).	1.54 E-2 (2/3)	

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Propachlor CAS No. 1918-16-7 EPA Chem Code: 019101	Likely (10/16/97)	Multiple tumors/multiple sites; Rare stomach tumor; Fischer 344 rat (M); Thyroid tumors & granulosa/theca cell tumors; Sprague-Dawley rats (M & F). Hepatocellular tumors; CD-1 mice (M).		
Comments: A linear low-dose a tumors (M mice)] &	approach (Q1*) for human risk chara non-neoplastic liver hypertrophy (cterization & extrapolation of risk should be based on both neoplastic mice) lesions.	[ovarian tumors (rats)	& liver
Propamocarb hydrochloride CAS No. 25606-41-1 EPA Chem Code: 119302	D (4/19/95)			
Comments: RFDC considered the	carcinogenicity phase of the rat	study to be unacceptable. The mouse carcinogenicity study was also cons	idered unacceptable.	
Propargite (Omite) CAS No. 2312-35-8 EPA Chem Code: 097601	B2 (7/23/92)	Statistically significant increases in undifferentiated sarcomas in the jejunum; Crl:CDBR rat (M & F).	2.01 E-1 (3/4)	
Comments: HCPRC determined th	ne mouse carcinogenicity study to b	pe inadequate. However a new study is not required.		
Propazine CAS No. 139-40-2 EPA Chem Code: 080808	C(q) (5/8/97)	Statistically significant increases in mammary gland adenomas, carcinomas and combined adenomas/carcinomas; Sprague-Dawley rat (F).	4.45 E-2 (3/4)	
Comments: HCPRC recommended	that for the purpose of risk charac	terization a low-dose extrapolation methodolgy (Q1*) be applied to the	animal <u>data.</u>	
Propetamphos CAS No. 31218-83-4 EPA Chem Code: 113601	Not likely (12/2/98)			
Propiconazole (Banner/Tilt) CAS No. 60207-90-1 EPA Chem Code: 122101	C (9/14/92)	Hepatocelluar adenomas, carcinomas, & adenomas/carcinomas combined; CD-1 mice (M).	1.79 E-2 (3/4)	Pending
based on the new d	ata submitted (90 day studies) Whic	mended that the Reference Dose approach should be used for quantification ch showed excessive toxicity at the high dose (2500 ppm); however, the managenic potential of Propiconazole.	n of human risk. This c niddle dose (500 ррж) wa	lecision was
Propylene oxide CAS No. 75-56-9 EPA Chem Code: 042501	B2 (CRAVE) (4/5/90)	Benign & malignant tumors at the site of exposure when exposed by subcutaneous injections (NMRI mice), by inhalation (F344/N, CpB:WU Wistar rats & B6C3F1 mice) & by gavage (Sprague-Dawley rats).	2.4 E-1 (0) 3.7 E-6 (I)	B2
Comments: This assessment is	located on IRIS. OPP has not review	ewed this chemical.		
Prosulfuron (CGA-152005) CAS No. 94125-34-5 EPA Chem Code: 129031	D (4/20/95)	Mammary gland adenomas & adenocarcinomas (F); Interstitial cell tumors (M); Crl:CD(SD)BR rats.		

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
ymetrozine CAS No. 123312-89-0 EPA Chem Code: 101103	Likely to be carcinogenic to humans (8/24/99)	Liver tumors- Hepatomas and combined adenomas and/or carcinomas; Tif:RAIf(SPF) Sprague-Dawley rats (F). Liver carcinomas and combined hepatomas and/or carcinomas; Tif:MAGf(SPF) mice (M & F).	1.19 E-2 (3/4)	
omments: For the extrapolat Committee also not	ion of risk to humans, the Committe ed that the metabolites of Pymetroz	e recommended using the linear low-dose (Q1*) approach based on liver t ine could be potentially carcinogenic since they are benzaldehyde or hy	umors by the oral route drazides,	e. The
yrethrins CAS No. 121-21-1 EPA Chem Code: 069001	Likely to be a human carcinogen by the oral route (4/8/99)	Liver tumors (F); Thyroid tumors (M & F); Charles River CD rats	5.14 E-3 (3/4)	
omments: The Committee reco based on the most	mmended a linear low-dose approach potent Q1* value of the two tumor t	for human risk characterization. For the linear low-dose (Q1*) approach ypes. This extrapolation is supported by the lack of data on the mode o	, extrapolation of risk f action for tumor indu	should buction.
yridaben CAS No. 96489-71-3 EPA Chem Code: 129105	E (5/11/94)			
yrimethanil CAS No. 53112-28-0 EPA Chem Code: 288201	C (2/12/97)	Thyroid follicular cell adenomas & combined adenoma/carcinoma (M); Thyroid cell adenomas (F); Sprague-Dawley rats.		
comments: KCPRC recommended admistration of Py	that a MOE methodology be used for rimethanil in Sprague-Dawley rats m	the estimation of human risk. The MOE methodology was selected because may be due to a disruption in the thyroid-pituitary status.	the thyroid tumors asso	ociated wi
yriproxyfen (Sumilarv) CAS No. 95737-68-1 EPA Chem Code: 129032	E (9/15/95)			
yrithiobac-sodium CAS No. 123343-16-8 EPA Chem Code: 078905	C(q) (9/5/95)	Liver adenomas, carcinomas & combined adenoma/carcinoma; CD-1 mice (M). Rare kidney tubular adenomas, carcinomas & combined adenoma/carcinoma; Crl:CDBR rats.	1.05 E-3 (3/4) 1.25 E-2 (3/4)	
comments: The HCPRC recommer tumors in the male	nded a low-dose extrapolation model e mouse (second Q1* value) and the c	be applied to the animal data for the quantification of human risk (Q1*combined kidney tumors in the male rat (first Q1* value).), for both the combine	ed liver
uinclorac (Facet) CAS No. 84087-01-4 EPA Chem Code: 128974	D (8/26/92)	Equivocal increase in pancreatic acinar cell adenomas; Wistar rats (M).		
uizalofop ethyl (Assure) CAS No. 76578-14-8 EPA Chem Code: 128201	D (3/17/88)	Liver (adenomas & carcinomas combined); CD-1 mice (M).		D
omments: HCPRC concluded th	nat limitations in the data from the	e mouse study precluded an accurate interpretation of carcinogenic risk.	. No new animals studies	s are

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Rimsulfuron (DPX-E9636) CAS No. 122931-48-0 EPA Chem Code: 129009	E (12/9/93)			
Rotenone CAS No. 83-79-4 EPA Chem Code: 071003	E (10/5/88)		<u> </u>	Deferred
Selenium and compounds CAS No. 7782-49-2 EPA Chem Code: 072001	D (CRAVE) (3/7/90)			D
Comments: Assessment based or chemical.	n inadequate human data & inadequate	e evidence of carcinogenicity in animals. This assessment is located on	IRIS. OPP has not revi	ewed this
Silver CAS No. 7440-22-4 EPA Chem Code: 072501	D (CRAVE) (9/22/88)	In animals, local sarcomas have been induced after implantation of foils & discs silver. Interpretation of these findings has been questions due to the phenomenon of solid-state carcinogensis.		D
Comments: This assessment is	located on IRIS. OPP has not review	wed this chemical.		·
Silvex (2,4,5-TP) CAS No. 93-72-1 EPA Chem Code: 082501	D (CRAVE) (12/2/87)			D
Comments: Assessment based or chemical. [Syn. Tri	n lack of data concerning carcinoge	nicity in humans & inadequate animal data. This assessment is located on	n IRIS. OPP has not rev	iewed this
Simazine CAS No. 122-34-9 EPA Chem Code: 080807	C(q) (5/24/90)	Pituitary gland carcinomas; Mammary gland carcinomas; Sprague-Dawley rats (F).	1.2 E-1 (2/3)	Pending
Sodium omadine CAS No. 15922-78-8 EPA Chem Code: 088004	D (5/16/95)	·		-
Comments: RFDC considered the	e mouse study to be inadequate.			
Spinosad (XDE-105) CAS No. 131929-60-7 EPA Chem Code: 110003	Not likely (6/17/97)			
Sulfentrazone CAS No. 122836-35-5 EPA Chem Code: 129081	E (5/7/96)			

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Sulfosate CAS No. 81591-81-3 EPA Chem Code: 128501	E (7/26/94)		<u> </u>	
Sulfosulfuron [MON 31500] CAS No. 141776-32-1 EPA Chem Code: 085601	Likely (10/28/98)	Rare transitional cell papilloma & carcinoma of the urinary bladder in females; Sprague-Dawley rats. Rare mesenchymaltumors of the urinary bladder in male as well as renal adenomas in male and female mice; CD-1	1.03 E-3 (3/4)	
Comments: The Committee recommends: benign mesenchymal	nmended that a linear low-dose appr tumors in male mice. This extrapo	roach (Q1*) for human risk characterization and extrapolation of risk sho Dation, rather than an MOE approach, is warrented due to lack of data or	ould be based on the in n mode of action.	ncidence of
Sulprofos (Merafos/Bolstar) CAS No. 35400-43-2 EPA Chem Code: 111501	E (3/26/96)			
TCMTB (Busan 72) CAS No. 21564-17-0 EPA Chem Code: 035603	C (8/28/96)	Testicular interstitial cell adenomas (M); Thyroid c-cell adenomas (F); Sprague-Dawley rats.		
Comments: HCPRC recommended	that for the purpose of risk charac	terization, the RfD approach should be used for quantitation of human r	isk	
Tebuconazole (Folicur) CAS No. 107534-96-3 EPA Chem Code: 128997	C (9/15/93)	Statistically significant increase in the incidence of hepatocell- ular adenomas, carcinomas & combined adenomas/carcinomas both by positive trend & pairwise comparisons; NMRI mice (M & F).		
Comments: HCPRC recommended	that for the purpose of risk charac	terization ther Reference Dose (RfD) approach should be used for quanti-	fication of human risk.	·
Tebufenozide CAS No. 5902-51-2 EPA Chem Code: 129026	E (8/29/94)			
Tebuthiuron CAS No. 34014-18-1 EPA Chem Code: 105501	D (3/1/91)			
Comments: RFDC considered the	e two mouse studies to be of supplo dy is not considered necessary at	ementary nature. Dose levels were inadequate for carcinogenicity testing this time.	; however tumor profile	was not
Terbacil CAS No. 5902-51-2 EPA Chem Code: 012701	E (9/30/94)			
Terbufos CAS No. 13071-79-9 EPA Chem Code: 105001	E (2/1/94)			

cancer.

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE
erbuthylazine CAS No. 5915-41-3 EPA Chem Code: 080814	D (8/24/94)	Benign interstitial cell tumors of the testes (M), mammary gland carcinomas (F); Tif:RAIF rats.		
Comments: Assessment based or same tumor types in	n statistically significant increas nduced by closely related analogs.	ses in tumors in the rat, only at a dose which the HCPRC considered exce	ssively toxic, but whi	ch were t
erbutryn CAS No. 886-50-0 EPA Chem Code: <u>0</u> 80813	C (3/3/88)	Mammary (adenomas/adenocarcinomas); Liver (adenomas/carcinomas) (F); Thyroid follicular (adenomas/carcinomas); Testicular interstitial cell adenoma (M); CR CD-1 mice.		
errazole CAS No. 2593-15-9 EPA Chem Code: 084701	B2 (1/9/91)	Multiple tumors (liver, bile duct, mammary gland, thyroid & testes) & cholangiocarcinoma (a rare tumor); Sprague-Dawley rats (M & F).	7.2 E-2 (M)	
etrachloroethane, 1,1,2,2- CAS No. 79-34-5 EPA Chem Code: 078601	C (CRAVE) (6/26/86)	Hepatocellular carcinomas; B6C3F1 mice (M & F).	2.0 E-1 (0) 5.8 E-5 (I)	C
omments: This assessment is	located on IRIS. OPP has not revi	ewed this chemical.		
etrachlorvinphos (Gardona) CAS No. 961-11-5 EPA Chem Code: 083701	C(q) (3/6/95)	Hepatocellular carcinomas & combined adenomas/carcinomas; B6C3F1 mice (F). Thyroid C-cell adenomas & adrenal pheochromocytomas; Sprague-Dawley rats (M).	1.83 E-3 (3/4)	
Tetraconazole CAS No. 112281-77-3 EPA Chem Code: 120603	Likely to be carcinogenic to humans (1/11/00)	Hepatocellular adenomas, carcinomas and combined adenomas/carcinomas in both sexes; Crl:CD-1 (ICR) mice	2.30 E-2 (3/4)	
Comments: For the quantifica tumors in male or	tion of human cancer risk, the Com female mice, whichever is more pot	mittee recommended a linear low-dose extrapolation (Q1*) approach based ent. This approach is supported by the lack of confirmation of the mode	on the incidence of co	ombined li azole.
Tetramethrin CAS No. 7696-12-0 EPA Chem Code: 069003	C (12/11/89)	Interstitial cell adenomas in the testes (M); CR CD-1 & CRCD Sprague-Dawley, Long-Evans Hooded rats.	!	
Comments: Quantitative estim	ation of potential human risk was	not recommended.		
Thallium(I) sulfate CAS No. 7446-18-6 EPA Chem Code: 080001	D (CRAVE) (11/8/89)			D
Comments: Assessment based o	n lack of data concerning carcinog	enicity in humans or animals. This assessment is located on IRIS. OPP ha	s not reviewed this c	nemical.
Thiabendazole CAS No. 148-79-8 EPA Chem Code: 060101	Likely to be carcinogenic to humans (2/24/00)	Thyroid follicular cell adenomas and combined adenomas/carcinomas; Sprague-Dawley Crl:CD BR rats	1.15 E-2 (3/4)	

chemcial.

OFFICE OF PESTICIDE PROGRAMS LIST OF CHEMICALS EVALUATED FOR CARCINOGENIC POTENTIAL

CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Not likely (7/16/97)			
Likely to be carcinogenic to humans (6/20/00)	Benign and malignant hepatocellular tumors in both sexes of Tif:MAG(SPF) mice	3.77 E-2 (3/4)	
or law-daca extrapolation (Q1*) and	proach for the quantification of numan cancer risk based on the most pot	ted at higher dose leve ent of the liver tumor	els. The CAR response
C (5/25/94)	Statistically significant increase in thyroid follicular cell tumors (M). Increases in renal tubular adenomas (M & F); however statistically significant positive trend in F only; Sprague-Dawley rats.		
that for the purpose of risk charac	cterization a Margin of Exposure (MOE) approach should be used for evalu	uation of the consequen	ces of humar
D (6/10/96)	Adenomas & carcinomas of the haderian gland; B6C3F1 mice (F).		
t the chemical should be classified	d Group D based on the possible potential of carcinogenic response which	n could not be ascertai	ned or
B2 (6/10/96)	Liver tumors (malignant & benign); CD-1 mice (M & F). Testicular interstitial cell tumors; Sprague-Dawley rat (M).	1.88 E-2 (3/4)	
that for the purpose of risk chara bined adenoma/carcinoma in male mi	cterization, a Margin of Exposure (MOE) methodology be used for the est	imation of human risk,	based on
Likely to be carcinogenic to humans (8/24/99)	Hepatocellular adenomas (M & F); Combined adenomas, carcinomas and/or hepatoblastomas (M); CD-1 mice. Thyroid follicular cell adenomas (M & F); Thyroid follicular cell carcinomas as well as combined adenomas and/or carcinomas (M); F344 rats.	1.38 E-2 (3/4)	
racterization, CARC recommended th by the lack of confirmation of the ce.	e extrapolation of risk using the linear low-dose (Q1*) default approach mode of action, concern for mutagenicity & dose-dependent increases in	h for liver tumors. Thi the incidence of liver	s extrapola tumors in
D (CRAVE) (9/15/87)			D
	AND DATE OF CLASSIFICATION Not likely (7/16/97) Likely to be carcinogenic to humans (6/20/00) were observed in rats, a hepatocar are low-dose extrapolation (01*) apprints approach is supported by the C (5/25/94) that for the purpose of risk characterization (6/10/96) that for the purpose of risk characterization, CARC recommended the by the lack of confirmation of the ce.	Not likely (7/16/97) Benign and malignant hepatocellular tumors in both sexes of thumans (6/20/00) Tif:MAG(SPF) mice	Not likely (7/16/97) Likely to be carcinogenic to humans (6/20/00) Benign and malignant hepatocellular tumors in both sexes of 13.77 E-2 (3/4) mere observed in rata, a hepatocarcinogenic response cannot be ruled out because the animals were not tested at higher dose levar low-dose extrapolation (01*) approach for the quantification of human cancer risk based on the most potent of the liver tumor his approach is supported by the lack of confirmation of the mode of action of this however statistically significant increase in thyroid followare call tumors (M). Increases in renal tubular aderomas (M & F); however statistically significant positive trend in F only; Sprague-Dawley rats. that for the purpose of risk characterization a Margin of Exposure (MOE) approach should be used for evaluation of the consequent of the chemical should be classified Group D based on the possible potential of carcinogenic response which could not be ascertaic existing mouse data. B2 (6/10/96) Liver tumors (malignant & benign); CD-1 mice (M & F). Testicular interstitial cell tumors; Sprague-Dawley rat (M). Liver tumors (malignant & benign); CD-1 mice (M & F). Testicular interstitial cell tumors; Sprague-Dawley rat (M). Likely to be carcinogenic to human significant page of risk characterization, a Margin of Exposure (MOE) methodology be used for the estimation of human risk, bined adenoma/carcinoma in male mice. Likely to be carcinogenic to humans (8/24/99) Hepátocellular adenomas (M & F); Corbined adenomas, carcinomas (M and Carcinomas) (M & F). Thyroid follicular cell arcinomas as well as combined adenomas and/or carcinomas (M); F3/4 rats.

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
oxaphene (Campechlor) CAS No. 8001-35-2 EPA Chem Code: 080501	B2 (CRAVE) (3/5/87)	Hepatocellular carcinomas & neoplastic nodules (adenomas); B6C3F1 B6C3F1 mice (M & F). Thyroid tumors (adenomas & carcinomas); Osborne-Mendel rats (M & F).	1.1 E+0 (0) 3.2 E-4 (I)	B2
omments: This assessment is	located on IRIS. OPP has not revie	wed this chemical.		
ralkoxydim CAS No. 87820-88-0 EPA Chem Code: 121000	Likely (10/22/98)	Benign Leydig cell tumors at all dose levels with the incidences at the high dose exceeding the concurrent & historical control; Wistar rats (M).	1.68 E-2 (3/4)	
comments: Committee recomment tumors of the test	ded that a linear low-dose (Q1*) fo es in male rats at all dose levels.	or human risk characterization & extrapolation of risk should be based o	n the occurrence of Le	ydig cell
riadimefon (Bayleton) CAS No. 43121-43-3 EPA Chem Code: 109901	c (12/4/96)	Borderline statistically significant increase thyroid adenomas; Wistar rats (M). Hepatocelular adenomas; NMRI mice (M & F).		
omments: HCPRC concluded th	at for the purpose of risk characte	erization, the RfD approach should be used for quantification of human r	isk.	
riadimenol (Baytan) CAS No. 55219-65-3 EPA Chem Code: 127201	C (1/29/88)	Liver (hepatocellular adenomas); CF1/W74 mice (F).		
riallate CAS No. 2303-17-5 EPA Chem Code: 078802	C(q) (1/12/94)	Hepatocellular carcinomas (M); Positive trend & a boderline significant increase in these tumors in females; B6C3F1 mice. Increased incidence of renal tubular cell adenoma (rare tumor type); Sprague-Dawley rat (M) [Considered biologically significant although no absolute pair-wise statistical significance was found].	7.17 E-2 (3/4)	
1 111	Triallate. If the Registrant choose However, if the Registrant decides	y study be repeated because the dosing was inadequate; the results are described to repeat the study, the decision on quantification risk will be defined to repeat the study, the existing low dose extrapolation (Q1*) base	erred diffit completion	M CADIMOLI
	E (3/11/91)			
riasulfuron (Amber) CAS No. 82097-50-5 EPA Chem Code: 128985			 	

Comments: The oncogenic response observed may be associated with a hormonal imbalance that may not occur at doses below an MTD. HCPRC conclued that a quantitative risk assessment is not appropriate because the increased incidence of mammary gland tumors was observed in female rats treated at dose levels exceeding the MTD, there was no evidence of genetic toxicity shown in several studies, and structural analogs of Express (other than Atrazine) were not associated with oncogenic responses in rats and mice.

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Tribufos (Tribuphos/DEF) CAS No. 78-48-8 EPA Chem Code: 074801	Likely (high doses); Not likely (low doses) (5/22/97)	Liver (hemangiosarcoma) (M), Lung (alveolar/bronchiolar adenoma) (F), Small intestine (adenocarcinoma) (M & F); CD-1 mice.	8.38 E-2 (3/4)	
Comments: A non-linear approa	ch (MOE) using the most sensitive	toxic endpoint considering all species tested was recommended for the pu	urpose of risk characet	erization.
Trichlorfon (Trichlorphon) CAS No. 52-68-6 EPA Chem Code: 057901	Likely (high doses), Not likely (low doses) (7/15/99)	Tumors of the kidneys (adenomas) in male F344 rats & tumors of the lungs in both sexes (adenomas/carcinomas in M; carcinomas in F). Mammary tumors in female CD-1 mice.		
pathological change	mice were observed at dose levels s; Mice: increased mortality and C loses that were excessively toxic.	that were considered excessively toxic (Rats: increased mortality, ChE hE inhibition). None of the tumors was considered to be relevant for hu	inhibition, non-neoplas man risk assessment bed	stic histo- cause they
Trichlorobenzene, 1,2,4- CAS No. 120-82-1 EPA Chem Code: 081101	D (CRAVE) (10/19/88)			D
Comments: Assessment based in chemical.	lack of data concerning carcinoge	nicity in humans & inadequate animal data. This assessment is located o	n IRIS. OPP has not re	viewed this
Trichloroethane, 1,1,1- CAS No. 71-55-6 EPA Chem Code: 081201	D (CRAVE) (8/5/87)			D
Comments: Assessment based or chemical.	n lack of data concerning carcinoge	enicity in humans & inadequate animal data. This assessment is located o	n IRIS. OPP has not re	viewed this
Trichloroethane, 1,1,2- CAS No. 79-00-5 EPA Chem Code: 081203	C (CRAVE) (7/26/86)	Hepatocellular carcinomas (M & F) and pheochromocytomas (F); B6C3F1 mice.	5.7 E-2 (0) 1.6 E-5 (I)	C
Comments: This assessment is	located on IRIS. OPP has not review	ewed this chemical.		
Trichlorophenol, 2,4,6- CAS No. 88-06-2 EPA Chem Code: 064212	B2 (CRAVE) (9/7/89)	Lymphomas or leukemias; F344 rats (M). Hepatocellular adenomas or or carcinomas; B6C3F1 mice (M & F).	1.1 E-2 (0) 3.1 E-6 (I)	B2
Comments: This assessment is	located on IRIS. OPP has not review	ewed this chemical.		
Triclopyr (salts & esters) CAS No. 55335-06-3 EPA Chem Code: 116001	D (5/8/96)	Classification based on increases in mammary tumors in rats (Fischer 344) & mice (Jcl:ICR), and adrenal pheochromocytomas in male rats, which the majority of the HCPRC believed to be only marginal.		
Triclosan (Irgasan) CAS No. 3380-34-5 EPA Chem Code: 054901	Not classifiable (10/22/98)			
Comments: The Committee was	unable to assign a carcinogenicity	classification to Triclosan, due to the lack of a second study in a sec	cond species.	

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
Tridiphane (Tandem) CAS No. 58138-08-2 EPA Chem Code: 123901	C (4/22/86)	Liver (hepatocellular adenomas, adenomas/carcinomas combined); B6C3F1 mice (F).		
Triflumizole CAS No. 08694-11-1 EPA Chem Code: 128879	E (8/10/93)			
Trifluralin (Treflan) CAS No. 1582-09-8 EPA Chem Code: 036101	C(q) (11/29/89)	Thyroid (follicular cell adenomas & carcinomas); Neoplasms of the renal pelvis (M); Benign urinary bladder tumors (F); Fischer 344 rats.	7.7 E-3 (2/3)	C
Comments: CRAVE Q* = 7.7 E-	3			
Triflusulfuron-methyl CAS No. 126535-15-7 EPA Chem Code: 129002	C (5/28/96)	Testicular interstitial cell adenomas; CD-1 rat (M).		
Comments: HCPRC recommended	that for the purpose of risk chara	cterization, the Reference Dose (RfD) approach should be used for quanti	tation of human risk.	
Triphenyltin hydroxide CAS No. 76-87-9 EPA Chem Code: 083601	B2 (5/24/90)	Pituitary gland adenoma (F); Leydig cell tumors (M); Wistar rat. Hepatocellular adenomas (M & F); combined hepatocelluar (adenomas and/or carcinoma) (F); NMRI mice.	1.83 E+0 (3/4)	
Troysan polyphase (IPBC) CAS No. 55406-53-6 EPA Chem Code: 107801	Not likely (12/04/96)			
UDMH CAS No. 57-14-7 EPA Chem Code: 600018	B2 (7/26/91)	Multiple sites (eg. lungs, vessels, liver & kidney); Multiple species, strains & studies.	4.6 E-1 (2/3) (M) 3.1 E-1 (2/3) (F)	
Comments: UDMH is the metab	olite/breakdown product of Daminozi	de (Alar). [Syn. unsymmetrical 1,1-dimethylhydrazine]	······································	
UMP-488 (PAL 6000) CAS No. 111578-32-6 EPA Chem Code: 129025	E (5/6/94)			
Uniconazole (Prunit) CAS No. 83657-22-1 EPA Chem Code: 128976	c (10/11/90)	Hepatocellular adenomas, carcinomas & adenomas/carcinomas combined; CD-1 mice (M).		
Comments: Quantification of will be used for	potential human cancer risk, using the quantification of potential hum	g the low dose extrapolation model (Q1*) was not recommended. Therefore,	, the Reference Dose (R	fD) approac
Vinclozolin CAS No. 50471-44-8 EPA Chem Code: 113201	C (6/20/00)	Leydig cell adenomas; Wistar rats (M)	2.9 E-1 (3/4)	

Comments: From the CARC meeting of 4/19/00: Based on the review of available data, the CARC concluded that infants, children & adults would be protected from Vinclozolin induced testicular Leydig cell tumors through a non-linear assessment with a POD of 3 mg/kg/day & a MOE approach. The CARC determined that the mode of action for Vinclozolin related antiandrogenic effects in infants, children & adults is mediated via inhibition of androgen receptors.

CHEMICAL	CURRENT OPP CLASSIFICATION AND DATE OF CLASSIFICATION	TUMOR TYPE / SPECIES	POTENCY Q* VALUE	CRAVE CLASS
White phosphorus CAS No. 7723-14-0 EPA Chem Code: 066502	D (CRAVE) (6/15/90)			D
Comments: Assessment based	on lack of data concerning carcinog	enicity in humans or animals. This assessment is located on IRIS. OPP ha	s not reviewed this	chemical.
Xylenes CAS No. 1330-20-7 EPA Chem Code: 086802	D (CRAVE) (12/2/87)			D
Comments: Assessment based chemical.	on lack of data concerning carcinog	enicity in humans & inadequate animal data. This assessment is located o	n IRIS. OPP has not	reviewed this
Zinc and compounds CAS No. 7440-66-6 EPA Chem Code: 129015	D (CRAVE) (6/15/90)			D
Comments: Assessment based	on inadequate evidence in humans &	animals. This assessment is located on IRIS. OPP has not reviewed this	chemical.	
Ziram CAS No. 137-30-4 EPA Chem Code: 034805	Likely to be carcinogenic to humans (4/6/00)	C-cell thyroic tumors and hemangiomas; F344 & CD rats (M) Alveolar/bronchiolar adenomas & combined adenomas/carcinomas; B6C3F1 mice (F)	6.11 E-2 (3/4)	
Comments: CARC recommended This approach is	a linear low-dose extrapolation (Q1 supported by the findings of benign	 approach for the quantification of human cancer risk based on C-cell lung tumors in female mice, lack of mode of action data, and the mutage 	thyroid tumors in ma nicity evidence of a	ale F344 rats. Ziram.